Optimised plasmids for sustained transgene expression in vivo by Magnusson, Terese
Dissertation 
zur Erlangung des Doktorgrades 
der Fakultät für Chemie und Pharmazie der 
Ludwig-Maximilians-Universität München 
 
 
 
Optimised plasmids for sustained transgene expression in vivo 
 
vorgelegt von 
Terese Magnusson 
aus Vilhelmina, Schweden 
2010
  
Erklärung 
Diese Dissertation wurde im Sinne von § 13 Abs. 3 bzw. 4 der Promotionsordnung 
vom 29. Januar 1998 von Professor Dr. Ernst Wagner betreut.  
 
 
 
Ehrenwörtliche Versicherung 
Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet. 
 
 
München, am ……………………. 
 
 
 
 
 
 
 
         …………………………… 
         (Unterschrift des Autors) 
 
 
 
Dissertation eingereicht am 15.10.2010 
1. Gutacher: Prof. Dr. Ernst Wagner  
2. Gutacher: PD Dr. Manfred Ogris 
Mündliche Prüfung am 25.11.2010 
 
  
1 Introduction  I 
Table of Contents 
1. INTRODUCTION .................................................................................................1 
1.1. Gene therapy............................................................................................................................................1 
1.2. Non-viral vectors for gene therapy ........................................................................................................2 
1.2.1. Cis-acting transcriptional regulators .....................................................................................................2 
1.2.2. Bacterial DNA as trigger for immune responses ..................................................................................5 
1.2.3. Difference between bacterial and vertebrate DNA ...............................................................................6 
1.2.4. TLR-9 ...................................................................................................................................................6 
1.2.5. CpG´s and their adverse effect on transgene expression ......................................................................8 
1.2.6. Reducing the number of CpG´s in plasmids .......................................................................................12 
1.2.7. Mini-circles.........................................................................................................................................13 
1.2.8. S/MAR´s .............................................................................................................................................14 
1.3. Aim of the thesis.....................................................................................................................................16 
2. MATERIALS AND METHODS ..........................................................................17 
2.1. Cloning and propagation of plasmids ..................................................................................................17 
2.2. In vitro studies .......................................................................................................................................18 
2.2.1. Cell lines and cell culture conditions ..................................................................................................18 
2.2.2. Isolation of primary porcine smooth muscle cells (PSMC´s) .............................................................19 
2.2.3. In vitro transfections ...........................................................................................................................20 
2.3. In vivo studies ........................................................................................................................................22 
2.3.1. Hydrodynamic delivery ......................................................................................................................22 
2.3.2. Xenograft implantation and electroporation .......................................................................................22 
2.3.3. In vivo imaging...................................................................................................................................22 
2.3.4. Isolation of tumour cells .....................................................................................................................23 
2.4. Luciferase-assay.....................................................................................................................................23 
2.4.1. Firefly luciferase.................................................................................................................................23 
2.4.2. Gaussia luciferase ...............................................................................................................................24 
2.5. Q-PCR ....................................................................................................................................................24 
3. RESULTS ..........................................................................................................26 
1 Introduction  II 
 
3.1. Comparison of human versus murine CMV enhancer and their effect on transgene expression in 
vivo 26 
3.2. Influence of immune status on transgene expression in vivo .............................................................30 
3.3. Plasmid retention in a tumour model ..................................................................................................32 
3.4. Evaluation of a novel synthetic promoter, SCEP, in vivo ..................................................................37 
3.5. Comparison of minicircles with full-length plasmid...........................................................................39 
3.6. Transcriptional targeting with liver specific promoters ....................................................................42 
4. DISCUSSION.....................................................................................................48 
4.1. Human CMV enhancer leads to higher expression and better plasmid retention than murine 
CMV enhancer .....................................................................................................................................................48 
4.2. Adaptive immune system is involved in transgene regulation in vivo ..............................................51 
4.3. Plasmid retention is dependent on cell growth activity......................................................................54 
4.4. Efficient immune response requires minimal amount of transgene..................................................56 
4.5. Minicircles lead to enhanced transgene expression in vivo................................................................57 
4.6. Transcriptional targeting with AFP promoter/CMV enhancer ........................................................59 
5. SUMMARY ........................................................................................................60 
6. APPENDIX.........................................................................................................63 
6.1. Abbreviations.........................................................................................................................................63 
6.2. Publications ............................................................................................................................................67 
6.2.1. Poster presentations ............................................................................................................................67 
6.2.2. Publications ........................................................................................................................................67 
7. REFERENCES ..................................................................................................69 
8. ACKNOWLEDGEMENTS..................................................................................79 
9. CURRICULUM VITAE .......................................................................................80 
1 Introduction  1 
 
1. Introduction 
1.1. Gene therapy  
Gene therapy is a technique to introduce genetic material into patients for treating or 
preventing inherited or acquired disease, such as cancer and certain viral infections. 
The success of gene therapy is largely dependent on an efficient and safe gene 
transfer to the host cells or tissue and the appropriate expression of the introduced 
gene. For the gene transfer there basically exist 2 major branches; viral and non-viral 
vectors. The virally based vectors make use of the evolutionary adapted ability of 
virus particles to efficiently transduce their target cells. But evolution also led to 
powerful defence mechanism against the viral attack, leading to a fast immune 
answer from the hosts innate immune system and subsequent specific humoral 
and/or cell-mediated immune response directed against viral epitopes. This can not 
only hamper gene transfer but also lead to serious side effects, and in extreme cases 
causing death [1]. Another disadvantage of viral systems concerns the use of 
retroviruses, which integrate their DNA load into the host genome. This leads on the 
one hand to stable transgene retention, but is on the other hand connected with the 
dangers of insertional mutagenesis [2, 3], for example the introduction of a strong 
promoter upstream of an oncogene or disruption of the reading frames of vital genes.   
Non-viral vectors, i.e. plasmid vectors, are generally safer, with less pronounced 
immunologic responses and low integrating potential, but suffer from a lower 
efficiency. Plasmid DNA (pDNA) can be delivered alone, for example by injection into 
muscle tissue or injection by hydrodynamic based methods, but is in most cases 
dependent on a carrier system which provide for shielding, targeting and cellular 
uptake of the DNA. Once released in the cytosol of the cell the plasmid must be able 
to fulfil its assignment of rendering a durable expression of the transgene at 
therapeutic levels. To implement this, the nature of the plasmid is decisive and the 
following passages will focus on the hurdles in transgene expression from pDNA and 
how an appropriate plasmid design can overcome them.   
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1.2. Non-viral vectors for gene therapy 
1.2.1. Cis-acting transcriptional regulators 
With the ambition of designing an optimised expression plasmid for gene therapy 
there are several aspects to consider. The choice of appropriate cis-acting 
transcriptional regulators, i.e. enhancers and promoters, is of immense importance, 
since they form the basis of a functional mammalian transgene expression, dictating 
the frequency of transcriptional initiation and therefore expression strength. 
Promoters can be divided into core and proximal promoters [4-6], depending on their 
position and function. The core promoter encompasses the transcriptional start site 
and contains the minimal sequences for correct initiation of RNA polymerase II 
(RNAPol II), i.e. binding sites for RNAPol II and basal transcription factors [4, 6]. It 
therefore is found in the absolute vicinity of the transcriptional start site (approx. +/-34 
- 40bp) [4-6], whereas the proximal promoter can be located within a couple of 
hundred base pairs upstream or downstream of the transcriptional start site (approx. 
+/-250bp) [4] and contains only binding sites for transcription factors [4, 6]. The core 
promoter can contain motifs such as the TATA-box, TFIIB recognition element 
(BRE), initiator (Inr) and down-stream promoter elements (DPE) [4-6]. Each of these 
elements has specific functions related to transcription and is found in some, but not 
in all, core promoters [4]. There is no universal core promoter and its structural 
diversity together with its cognate cis-acting regulatory sequences, such as proximal 
promoters, enhancers and insulators, enables a differentiated expression as a 
response to changes in the nuclear environment.  
The enhancer element differs from the promoter by not being orientation dependent 
and can act from large distances, up to many kb, away from the transcription start [6, 
7]. In the event of transvection the enhancer even functions in trans to activate an 
allelic promoter on the other chromosome [7, 8]. The enhancer influences 
transcription from the distance by looping of the DNA, which brings the enhancer and 
core promoter in close proximity [7, 9, 10], enabling an orchestrated and interacting 
assembly of the enhanceosome (enhancer and associating transcription factors) and 
the transcriptional pre-initiation complex [11, 12]. Evidence show that the interaction 
is based on protein-protein interactions between transcription factors bound to the 
enhancer and promoter [7, 10], which could be the reason for the, in some cases, 
observed enhancer-promoter specificity. In these cases the enhancer increases 
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transcription from certain types of core promoters better [13, 14], or exclusively from 
certain promoters [15-18]. This probably serves to limit enhancer action to its 
designated promoters, since it is able to regulate gene transcription over large 
distances, hence, could otherwise also influence other promoters. Another way of 
regulating enhancer action are insulator regions, which limit the enhancer area of 
action within the insulator boundaries [6]. 
In plasmid design, viral promoters and enhancers are common features and the most 
extensively used originates from the cytomegalovirus (CMV). The genome of CMV is 
divided into 3 domains, depending on the temporal expression of the genes therein: 
immediate early, early and late. The immediate early genes are transcribed 
immediately after transduction, i.e. in acute infection, without the need for virally 
encoded proteins -but are silent in latency [19]. The major immediate early enhancer-
containing promoter sequence (CMV-IEP) consist of a core promoter and a partially 
overlapping enhancer element, which together switch transcription on and off 
dependent on the status of the host immune system and cellular transduction 
processes [19]. The enhancer is a complex modular multicomponent region 
containing numerous binding sites for transcription factors, many of them repeated 
numerously [20]. Examples thereof are the 19-nucleotide repeats which contain 
binding sites for CRE (cyclic AMP response element) [21] and the 18-nucleotide 
repeats which specifically bind NFκB (nuclear factor κB)[22]. The sequence of the 
enhancer has been optimized to the respective host, hence, there exists a common 
basic blueprint with host specific variances. Many of the regulatory elements are 
conserved amongst the species strains of CMV, but the arrangement and number of 
transcription factor binding sites differ between them [23, 24]. Nevertheless, there 
also exist unique transcription factor binding sites, such as Elk-1, serum response 
factor, CBP and gamma-interferon activating site, which are only found in human 
CMV (hCMV) [23]. The close interrelation and still distinct functionality of the CMV 
enhancers has been demonstrated by replacing the enhancer of the murine CMV 
(mCMV) with the hCMV enhancer in vitro without changing the wild-type 
characteristic growth of mCMV in murine cells [24]. But the other way around, 
replacing the enhancer in hCMV with the murine analogue resulted in less efficient 
replication in human cells [25]. 
The CMV promoter might still be the most commonly used promoter since it renders 
strong and ubiquitous expression. But because of the reported fast inactivation by 
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promoter methylation [26, 27] other ubiquitous promoters are being investigated, for 
example the promoter of the elongation factor 1α (EF-1) or β-actin gene [28]. There 
are also other reasons for exchanging the CMV promoter. Depending on the gene 
therapy approach, it can be advantageous to limit the transgene expression. This can 
be achieved both in a temporal and tissue-specific manner by choosing a functional 
promoter and contingent auxiliary cis-acting modules. A temporal expression 
limitation is obtained by using an inducible expression system. It is based on a 
promoter which is activated by the presence or absence of biotic or abiotic factors, 
such as arabinose [29-31], antibiotics [32, 33] or heat [34-38].  A spatial expression 
limitation is acquired by using a tissue specific promoter which is active only in 
specific cellular environments. This so called transcriptional targeting can be a part of 
the overall targeting mechanism of the gene therapy complex, complementing a 
cellular targeting function of the plasmid carrier system, or act on its own.  The field 
of transcriptional targeting was pioneered by Vile and Hart in 1993: They used 5´-
control regions of genes related to melanin production (tyrosinase and tyrosinase 
related protein 1) to achieve gene expression explicitly in melanocytes, which are the 
natural melanin producing cells [39]. Since then the number of promoters used for 
transcriptional targeting has risen substantially. Particularly in the field of cancer gene 
therapy, this technique is of special interest. It aims to specifically kill the cancer cells 
and avoid off-target expression of, for example, a cytotoxic compound or a suicide 
gene, in normal tissue, which otherwise could have a devastating effect. Some 
promoters currently used for cancer gene therapy -in addition to the aforementioned 
tyrosinase promoter for melanocytes/melanoma, are prostate specific antigen (PSA), 
prostate specific membrane antigen (PSMA), probasin and human glandular 
kallikrein (hK2) promoter for prostate targeting, glial fibrillary acidic protein (GFAP), 
myelin basic protein (MBP) and myelin proteolipid protein promoter for glial/glioma 
targeting [40], just to mention a few. The disadvantage of tissue specific promoters is 
in general that they do not distinguish between healthy and cancerous tissue. 
Because of this, their use in cancer treatment is limited to cancer types originating 
from non-vital organs, for example melanoma, prostate or ovarian cancer. 
Alternatively, a promoter specific for tumour cells has to be used. For example, the 
promoter of albumin has been used for specific expression in hepatocytes [40, 41], 
but would be inappropriate for gene therapy of hepatomas with a direct or indirect 
cytotoxic gene, since normal hepatocytes would also be affected. One alternative to 
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the albumin promoter in liver cancer treatment is the tumour specific promoter 
derived from the α-fetoprotein (AFP) gene, which is normally only transcribed in 
foetal hepatocytes, but is reactivated in most hepatocellular carcinomas (HCC) [42]. 
The AFP promoter has been used with viral vectors, for example by promoting the 
expression of NIS (sodium iodide symporter) and consequent treatment with 
radioiodine [43-45], or HSV tk (herpes simplex virus thymidine kinase) and 
consequent treatment with the prodrug ganciclovir which is transformed into its toxic 
form by the TK [42, 46-49]. Also, the AFP promoter has been used for triggering the 
oncolytic activity of recombined adenovirus [50]. All approaches are showing 
promising results with a good transcriptional targeting with the AFP promoter, but so 
far no work has been done with non-viral vectors. 
 
1.2.2. Bacterial DNA as trigger for immune responses 
A prerequisite for a strong and enduring transgene expression are efficient promoter 
and enhancer elements, but they do not help if the transgene vector is silenced by 
the host cell, or even disposed of by the immune system. These events are common 
problems in gene therapy and they are caused by specific dinucleotides commonly 
found in bacterial DNA. The discovery of bacterial DNA as a trigger of immunological 
reactions was first done by the group around Tokunaga in 1984. They examined the 
bacille Calmette-Guérin (BCG)-mediated anti-tumour effect and by treatment with a 
DNA-rich BCG-fraction they observed regression and/or prevented metastasis of 
tumours in mice and guinea pigs [51]. In vitro they could show an augmentation of 
natural killer cell (NK) activity in peripheral blood lymphocytes by incubation with the 
same bacterial isolate [52] and the release of type I and type II interferon (IFN) [53]. 
The idea that bacterial DNA in general could be mitogenic was independently 
investigated by Pisetsky et al by observing the proliferation of murine lymphocytes 
after treatment with DNA from different bacterial strains, whereas no effect was seen 
after treatment with vertebrate DNA. They postulated that this effect must come from 
“non-conserved structural determinants”, which do not exist in vertebrate DNA [54]. 
Shortly thereafter, the group of Tokunaga also observed the differential mitogenic 
activity of bacterial and vertebrate DNA [55]. Krieg et al then discovered that specific 
CpG-containing motives in bacterial DNA trigger B-cell activation [56].  
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1.2.3. Difference between bacterial and vertebrate DNA 
In comparison to bacteria and some viruses, which show the mathematically 
expected frequency of CpG-dinucleotides in the genome (1:16), vertebrate DNA is 
CpG suppressed, with a frequency of only one-fifth of the expected density [57]. 
Furthermore, in vertebrates about 80 % of the CpG´s are methylated at position 5 at 
the cytosine ring, which incapables the dinucleotides to an immunogenic stimulation, 
while bacterial DNA is largely unmethylated [56, 57]. This links the CpG-suppression 
of vertebrate DNA to the non-self pattern recognition by the immune system. The 
sparsity of CpG´s in the vertebrate genome is probably the result of the non-
existence of an effective repair mechanism of deaminated 5-methylcytosin, which 
gives thymine [14, 57]. 
 
1.2.4. TLR-9 
Bacterial DNA, with its higher frequency of non-methylated CpG-dinucleotides, and 
CpG-containing oligodeoxynucleotides (ODN´s), are highly stimulatory to leukocytes 
in vitro, inducing B-cell proliferation and immunoglobulin secretion [56], NK cell lytic 
activity [58] and dendritic cell (DC) [59] and macrophage [60] activation. The 
activation of these diverse events by unmethylated CpG´s has its triggering point at 
the toll-like receptor (TLR) 9, a member of the big evolutionary conserved TLR family. 
TLR´s recognize different pathogen-associated molecular patterns (PAMP´s) in 
mammals [61]. For example, TLR4 specifically binds to lipopolysaccharide (LPS), a 
component of the outer wall of gram negative bacteria, and the ligand of TLR8 is 
single stranded RNA of viruses [62]. TLR-9 was first recognized as the mediator of 
cellular response to unmethylated CpG in 2000 in the group of Akira [63]. They 
treated TLR-/- mice with bacterial DNA, which in this case were not able to elicit any 
of the characteristic immunologic events which are known to be triggered by 
unmethylated CpG-containing DNA. 
TLR9 consist of, as every TLR in general, a leucin-rich repeat (LRR), a 
transmembrane component and a Toll/IL-1 receptor (TIR) homology domain (fig.1), 
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the latter receiving its name because of the 3 homologous regions (Box 1-3) with the  
IL-1 (interleukin 1) receptor [61-63]. TLR-9 is first located in the endoplasmic 
reticulum (ER) of macrophages and DC´s and then translocates to compartments 
containing exogenous DNA, which are early endosomes directly after endocytosis of 
bacteria and at a later stage motile lysosomal compartments. The TLR-9 directly 
binds to the ligand DNA [64] with the receptor LRR´s which is located in the 
 
 
Fig. 1: Transduction pathway of TLR9. The transmembrane receptor TLR9 binds unmethylated 
CpG motifs of endocytosed DNA in the lysosomal lumen. The binding leads to formation of a 
multiprotein complex with MyD88, IRAK1, IRAK4 and TRAF6 on the cytosolic part of TLR9 (TIR). 
IRAK1 and TRAF6 dissociate and form a new complex with TAB1, TAB2 and TAK1 on the 
lysosomal membrane. IRAK1 is degraded and the complex binds UEV1a and UBC13, which 
activates TAK1 to phosphorylate MAP kinase and IKK complex. IKK in turn phosphorylates IκB, 
which is then ubiquitylated and degraded, thereby releasing NFκB to translocate to the nucleus 
and bind to NFκB binding motifs on the genome. AP-1 is activated by phosphorylation by MAP 
kinases and likewise binds to its corresponding genome sequences. As a result of NFκB and AP-1 
binding, the expression of proinflammatory cytokines is triggered.  
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lysosomal lumen, whereas the TIR domain is protruding into the cytoplasm for 
consequent transduction signalling [65]. Upon receptor-ligand binding MyD88 
(myeloid differentiation primary-response protein 88) is recruited to the TIR domain, 
where it in turn associates with IRAK4 (IL-1R associated kinase 4). IRAK4 in turn 
binds to IRAK1 and triggers its phosphorylation. The phosphorylated IRAK1 
associate with TRAF6 (tumour necrosis factor receptor associated factor 6) and the 
IRAK1/TRAF6 heterodimer dissociate from the receptor and forms a new complex 
with TAK1 (transforming growth-factor-β-activated kinase), TAB1 (TAK1-binding 
protein 1) and TAB2 at the lysosomal membrane. IRAK1 is degraded and the 
remaining TRAF6/TAK1/TAB1/TAB2-complex binds to UBC13 (ubiquitin-conjugating 
enzyme 13) and UEV1A (ubiquitin-conjugating enzyme E2 variant 1) in the cytosol. 
This leads to the ubiquitylation of TRAF6 which, in turn, activates TAK1. The 
activated TAK1 phosphorylates MAP (mitogen-activated protein) kinases and the 
IKK-complex (IκB-kinase complex, consisting of IKK-α, IKK-β and IKK-γ). The 
activated IKK-complex subsequently phosphorylates IκB (inhibitor of NFκB), which 
leads to its ubiquitylation and degradation. The NFκB, released from IκB, then 
translocates to the nucleus and activates expression from NFκB-dependent genes 
[62]. Together with AP-1 (activating protein-1), which is activated by MAP-kinases, 
NFκB lead to the expression of pro-inflammatory cytokines, like TNF-α (tumour 
necrosis factor- α), IL-1 (interleukin-1), IL-6 and IL-12 [65].  
 
 
1.2.5. CpG´s and their adverse effect on transgene expression 
1.2.5.1. Immune response 
Unmethylated CpG dinucleotides can, as explained above, elicit a direct 
inflammatory response. This effect has already been harnessed to improve the 
immune response after vaccination by using CpG-motifs as adjuvants [65, 66] or for 
cancer immune therapy approaches [67]. In the context of gene therapy where a 
long-term transgene expression is desired, CpG-dinucleotides in the plasmid DNA 
have been shown to have a strong negative effect on the duration of transgene 
expression [68-72]. Even as few as one CpG dinucleotide in the plasmid DNA 
sequence can lead to increased levels of pro-inflammatory cytokines (TNF-α, IL-12, 
IFN-γ) and infiltrating neutrophils; additional CpG´s increased these levels 
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incrementally, whereas CpG-depleted plasmids showed no measurable elevation of 
the cytokine levels [69].  
The mechanism by which unmethylated CpG-sequences reduces transgene 
expression is not entirely clear, but could derive from various factors. First, 
proinflammatory cytokines, such as Il-1, Il-6 and TNF-α, produced as a result of 
interaction of unmethylated CpG´s with TLR-9 in immune cells, can cause local 
tissue injury by inducing the production of nitric oxygen and reactive oxygen species 
intermediates. This injury can lead to further expression of chemokines and 
chemokine receptors, attraction of neutrophils and macrophages and activation of 
local endothelium and epithelium. This leads to elevated expression levels of 
adhesion molecules, chemokines and subsequent the attraction of antigen-
dependent and –independent inflammatory cells to the site of inflammation [73]. The 
interaction of the unmethylated CpG DNA with the TLR-9 also activates DC´s and B 
cells and triggers the expression of costimulatory and class II MHC (major 
histocompatibility complex) molecules and chemokine receptors, preparing them for 
acting as a professional antigen presenting cell (APC) and migration to draining 
lymph nodes for interaction with T-cells. After internalization and processing of the 
antigen (in the case of plasmid vectors: the transgene product) B-cells can home with 
T helper (TH) cells, thus being primed to become antibody producing plasma cells, 
and DC´s can activate naïve T cells, which once activated, will secrete cytokines to 
further strengthen the adaptive immune response [74]. The adaptive immune system 
needs three signals to develop an efficient immunological reaction against an antigen 
[74]: The first signal comes from the antigen itself, i.e. the transgene product. The 
second signal is derived from a co-stimulatory molecule, like CD80 or CD86, which 
itself is induced from the third signal, deriving from a PAMP. In the case of plasmid 
DNA vectors, the PAMP will be the unmethylated CpG sequences, which trigger 
TLR9 and subsequent gene expression of co-stimulatory molecules. That this third 
signal, the activation of the APC, can have a strong effect on the immune reaction 
against the transgene product was shown by Ertl and co-workers [75] in mice 
injected i.m. with plasmids, expressing an antigenic viral glycoprotein. The plasmid 
contained immunostimulatory CpG sequences and by methylation of the plasmid 
(containing a methylation-insensitive SV40 promoter) the longevity of the transgene 
expression was markedly increased, and also, the maturation and migration of DC´s 
to the lymph nodes were reduced. This result points to the importance of an 
1 Introduction  10 
 
activated, mature professional APC in the initiation of an adaptive immune reaction 
directed against a transgene product. Hence, unmethylated CpG-motifs can cause a 
general ‘alert status’ of the innate immune system which in turn can activate 
transgene product specific B and T cells. 
1.2.5.2. Promoter attenuation: 
Another mechanism for CpG-mediated reduction of transgene expression is the 
attenuation of promoters, where the transfected cells are not killed, but the transgene 
expression itself is reduced. The effect seems to be on the level of mRNA and does 
neither alter the cell viability nor causes vector reduction [77]. It has for example 
been shown, that the CMV promoter can be attenuated by exposure to the cytokines 
IFN-γ [76-80] and IL-10 [79]. Other viral promoters which are sensitive to IFN-γ 
originate  from the simian virus 40 (SV40) [76, 77], rous sarcoma virus (RSV) [77] 
and hepatitis B virus (HBV) [81]. In the case of mCMV, IFN-responsive elements 
were found scattered over the immediate early enhancer sequence, hence, IFN-γ 
probably reduced expression by transcription impairment [80]. Aside from diminution 
of expression there are also cases of augmentation by cytokines; the CMV promoter 
can be activated by TNF-α, IL-4 and IL-1 [79] and the MHC class I promoter is 
activated by IFN-γ [76]. 
1.2.5.3. DNA-methylation: 
Another negative effect on transgene expression deriving from unmethylated CpG´s 
not correlated to the destruction of the host cell, is plasmid methylation. The cytosine 
in the context of a CpG dinucleotide can be methylated in position 5, thus losing its 
immunogenic character, but instead this modification can perturb transcription.  It is 
generally accepted, that hypermethylated promoters lead to transcriptional silencing. 
About 60% of all genes, predominately house keeping genes and highly transcribed 
genes, contain in their 5´ end sequences dense stretches of CpG dinucleotides, the 
so called CpG islands [82],. These are normally unmethylated with hyperacetylated 
histones and are deficient in linker histones [83], whereas the vast majority of CpG´s 
scattered over the genome are methylated. Methylation of promoter CpG islands is 
seen as a mean for gene silencing [84], and plays a role in X-chromosome 
inactivation [85], genomic imprinting [86, 87], the silencing of intragenomic parasites 
[88], and carcinogenesis [89-91].  
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 The most direct way of gene silencing by promoter methylation is steric shielding by 
methyl groups of the binding sites of the basal transcription machinery and 
transcription factors. Many transcription factors contain GC-rich sequences or CpG 
dinucleotides in their DNA binding site. The methyl group of methylated CpG´s 
protrudes into the major grove of DNA and, thus, binding of transcription factors to 
methylated DNA can be hampered or abrogated. Some examples for methylation 
sensitive transcription factors are AP-2, c-Myc, CREB and ATF [92]. The direct 
masking of promoter and enhancers by methyl groups is not the only and also not the 
most prominent way of transcription interference. There are transcription factors 
insensitive to methylation, for example AP-1 and CTF [92] and many have 
recognition sites without CpG´s. Further, Kass et al [93] has shown that methylation 
alone does not silence gene expression but leads to formation of a repressive 
complex which excludes the transcriptional machinery from the promoter. They 
demonstrated that transcription can be executed equally well from a methylated or 
unmethylated plasmid with a HSV tk (herpes simplex virus thymidine kinase) 
promoter directly after injection into Xenopus oocyte nuclei. At later time points the 
expression from the methylated plasmid was gradually reduced in comparison to the 
unmethylated plasmid. This coincided with a gradual loss in DNAse I hypersensitive 
sites in the methylated plasmid (which is generally thought of as the transcription 
factor binding sites where nucleosomes are excluded) and inclusion of the promoter 
into a nucleosomal array. It demonstrates how the methylation is the trigger for a 
time-dependent assembly of a repressive structure that includes a higher order 
nucleosomal complex.  
The bridge between the methylated DNA and the repressive structure are methyl-
CpG binding proteins, for example MeCP2 and MBD1-3, which  attract corepressive 
proteins and histone deacetylases (HDAC´s) directing the remodelling of chromatin 
[82]. The MeCP2, for example, tethers a repression multiprotein complex that 
includes the corepressor protein mSin3A and the histone deacetylases HDAC1 and 
HDAC2 [94], and can operate over a distance of many hundred base pairs to induce 
repression [83]. The repressive effect could be abolished by treatment with histone 
deacetylases, indicating histone deacetylation as an essential component of the 
repression mechanism [94, 95]. 
The transcriptional repression mediated by methylation does not work as an on-off 
button, but can be graded according to various factors. Expression experiments with 
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patch-methylated plasmid vectors have led to deeper understanding of the 
relationship between reduced expression and methylation density and position. The 
effect of repression is transmissible in cis, which means that a methylation of the 
promoter is not required, but can spread from adjacent areas [93, 96-98].  The 
proximity of the methylated patch to the promoter seems in lesser extent to be 
decisive for repression than the number of methylated CpG´s [96-98]. The formation 
of a repressive chromatin complex is induced by methylated DNA and spreads onto 
unmodified flanking domains. Parameters such as methylation density could 
influence the stability of the complex, thus its ability to diffuse on the plasmid and 
exert its anti-transcriptional function. For example, a sparsely methylated transgene 
could repress expression completely, but this effect could be overridden by the 
introduction of an enhancer sequence.  A densely methylated transgene, on the other 
hand, could not be saved from expressional repression by the enhancer. [99]. 
 
1.2.6. Reducing the number of CpG´s in plasmids 
Because of the disadvantageous effects of CpG´s in the plasmid vector listed above, 
such as activation of the immune system or silencing of the transgene, there are 
great efforts done in reducing or eliminating these dinucleotides. As a normal CpG-
replete plasmid contains several hundreds of CpG´s the method of site directed 
mutagenesis would be too labour intensive. Instead, synthetically manufactured DNA 
is used. The coding regions, such as transgene and antibiotic resistance genes, can 
be changed by using the degeneracy of the genetic code (codon optimization). 
Hence, the DNA sequence can be changed without perturbing the primary amino 
acid structure. Other functional DNA sequences, such as splice donor and acceptor 
and lariat branch point in introns must remain intact to excise its task. Promoters and 
enhancers can be CpG depleted, but with unforeseeable consequences of their 
functionality. Another regulatory sequence difficult to modify is the origin of replication 
(ori). Most commercially available plasmids have an ori based on the ColE1 ori [100], 
which transcribes for a short RNA primer initiating replication start [101]. About 60% 
of its CpG´s have successfully been substituted without extensive loss of activity, but 
a totally CpG free version is not possible [100]. As an alternative, the protein 
regulated replication of R6K is used. For this, the CpG-depleted γ-origin of replication 
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of R6K is incorporated into a plasmid, which is propagated in bacteria harbouring the 
pir-gene, over-expressing the π-protein, which initiates replication [102]. 
 
1.2.7. Mini-circles 
One alternative to the CpG-reducing modifications mentioned above is to eliminate 
the plasmid backbone containing the bacterial sequences, such as ori and antibiotic 
resistance genes with accompanying promoter, which contain a big part of the 
CpG´s. Also, as an effect of reducing the plasmid size, investigators have 
demonstrated that vector size has a substantial inverse impact on transgene 
expression level when transfected into mouse muscle in vivo by electroporation [103] 
or intra-arterial delivery, or delivered to HeLa cells in vitro [104], probably by 
facilitating the vector delivery.  
Linear DNA containing only the mammalian expression cassette produced by PCR 
was able to direct similar long-term transgene expression in vivo as the original 
plasmid vector (equimolar amounts), with the difference in inducing less TNF-α and 
IL-12 production [105]. A similar approach, but by producing a linear DNA expression 
cassette by endonuclease digestion of parental plasmid and subsequent purification, 
resulted in elevated transgene expression levels in mouse liver from the linear DNA 
compared to the circular plasmid [106]. 
The disadvantage with linear DNA is that the ends of the DNA molecule are exposed 
and can be targeted by exonucleases. For this reason, methods have been 
developed to manufacture a closed circular mammalian expression cassette by 
removing the bacterial backbone by intramolecular site specific recombination. Thus, 
two circular molecules are formed: one miniplasmid harbouring the bacterial 
sequences, such as bacterial promoter, antibiotic resistance gene and ori, and one 
with the mammalian expression cassette, the “minicircle”. In general, higher 
transgene levels are reported in vitro [29, 35] and in vivo [30, 34] from the minicircle 
compared to the full-length plasmid. For production by recombination it is crucial that 
the process is inducible, allowing a programmed start only after the growth phase in 
the bacteria, and a proper purification step, to separate the minicircle from the side 
product (miniplasmid and residual parental plasmid). Several types of recombinases 
have been tested. Darquet and co-workers [34-36]) have utilised the heat-inducible 
phage λ Int integrase to form minicircles which were isolated by restriction enzyme 
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digestion of the miniplasmid and subsequent caesium chloride centrifugation. 
Another recombinase system derived from the phage P1 Cre recombinase was used 
by Bigger and co-workers [29], putting the recombinases under the control of an 
arabinose operon. Also here, minicircle was isolated from side products by enzyme 
digestion and caesium chloride centrifugation. Nehlsen et al [37] used an agarose gel 
for separation of minicircle from the restriction enzyme digested side products after 
recombination with a heat-inducible Flp recombinase. An integrase from the phage 
ΦC31 was used for recombination by Chen et al [30, 31]. The recombinase and an 
endonuclease gene was put under the control of the arabinose inducible BAD 
promoter in the parental plasmid, allowing for recombination reaction at 32°C and 
subsequent digestion of side product plasmids at 37°C after adding arabinose to the 
bacteria medium. The minicircle could then be extracted by conventional plasmid 
isolation procedure from the bacteria. This direct in vivo separation of minicircle from 
side product plasmids has the advantage of being more efficient and less labour 
intensive than the previously described methods. Another efficient system of direct 
isolation of minicircle DNA was reported by Jechlinger et al. [38] using an arabinose 
induced expression of ParA resolvase and a minicircle-specific membrane anchor, 
which executes the formation of minicircles and the membrane anchorage thereof, 
respectively. After a heat-induced lysis of the bacteria the minicircle is found in the 
cell pellet whereas side product plasmids are in the supernatant. Of all recombinases 
the ParA resolvase is the most efficient in minicircle production with 100% 
recombination rate [38], which is also needed when using an affinity-based 
purification of the minicircle, since otherwise also residual parental plasmid would be 
co-purified. 
 
1.2.8. S/MAR´s  
For the design of an efficient plasmid for gene therapy approaches the choice of 
transcriptional regulators is crucial, as they dictate the basic transcriptional activity. 
Also, the CpG content should be minimized to circumvent transgene silencing and 
the loss of plasmid DNA by immunologic reactions. To further reduce the loss of 
plasmids it is also important that the plasmid is replicated properly in every cell cycle 
and segregated evenly onto the daughter cells in mitosis. Reports have shown that a 
scaffold/matrix attachment (S/MAR) sequence can support this [107, 108]. S/MAR´s 
1 Introduction  15 
 
are naturally occurring AT-rich sequences which organizes the genome by binding 
DNA loops to the nuclear matrix. S/MAR´s do not have a shared consensus, but the 
physical property of being able to relax base-pairing under torsional stress [109], and 
they are often found in association with origins of bidirectional replication [108]. The 
first episomal plasmids -plasmids able to stably remain as a autonomously 
replicating, extrachromosal entity in the nucleus- were dependent on virally encoded 
proteins, such as the large T-antigen from SV (simian virus) 40 or EBNA-1 from EBV 
(Epstein-Barr virus). These proteins were supporting replication by interacting with 
the ori of the plasmid but could lead to transformation of the transfected cells and 
tumour formation in vivo [109]. By exchanging the large T-antigen with an S/MAR 
sequence the first episomal plasmid devoid of virally encoded proteins was created, 
pEPI-1 [108]. pEPI-1 was stably remained in transfected cells without selection 
pressure over more than 100 cell generations, without integrating into the genome 
[108]. The minimal requirement for efficient plasmid retention was shown to be an 
S/MAR sequence downstream of the transgene, allowing for transcription into the 
S/MAR [107]. Also, it was shown that the S/MAR bound pEPI-1 to the nuclear matrix, 
by association to nuclear proteins such as SAF-A [107, 110, 111] and non-covalently 
to mitotic chromosomes [107]. By binding to the nuclear matrix replication, which is 
tightly associated with the matrix, can be facilitated, and by binding to mitotic 
chromosomes, a successful transmission into the daughter cell nuclei can be 
achieved. Both processes are possible contributors to the high retention potential of 
pEPI-1 (>0,98) [107]. The efficiency of pEPI-1 is only hampered by a low episomal 
establishment rate, and establishment in vitro is only achieved after an initial 
selection period [108]. 
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1.3. Aim of the thesis 
The aim of this thesis was to develop and explore new and better plasmid vectors for 
the purpose of ameliorated nonviral gene therapy. So far gene therapy in general is 
hampered by low safety in the case of viral delivery and low efficiency in the case of 
the nonviral vectors. By concentrating on the nonviral approach, the most imminent 
safety issue is solved, but the nonviral vectors still need improvements to meet the 
requirements posed on a gene therapy product. Such a requirement is a high and 
prolonged gene expression, thus delivering the gene product at therapeutic levels 
and circumventing repeated applications and the discomforts and costs associated 
with them. In this thesis this was aimed at by evaluating a combination of the 
ubiquitous mammalian promoter EF-1 with a murine or human CMV enhancer in 
vivo. Also, a promising novel synthetic promoter, SCEP, was investigated. The 
transgene expression was measured over an extended period of time to follow the 
long-term stability and allow a better understanding to why transgene signal is lost, 
in order to further improve plasmid design. Additionally to the EF-1 and SCEP 
promoter, liver specific promoters were examined for transcriptional targeting of the 
liver, which can be useful in avoiding off-target expression, thus reducing side-
effects of a liver specific gene therapy. 
A further aim of this thesis is the testing of a minicircle, produced by a novel and 
highly efficient production and purification process. By comparison with its parental 
plasmid in vivo conclusion were drawn about its functionality and advantages of 
avoiding the bacterial backbone. 
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2. Materials and methods  
2.1. Cloning and propagation of plasmids 
The plasmid pCpG-mCMV/EF1-LucSH was cloned by inserting the BglII-NehI-
digested Luc::Sh fusion gene from pMOD-LucSh (Cayla-Invivogen, Toulose, France) 
in the BglII-NehI-digested backbone of pCpG-mcs (Cayla-Invivogen). The resulting 
plasmid is CpG-depleted and driven by an EF-1 promoter. For the pCpG-hCMV/EF1-
LucSH the murine CMV enhancer of pCpG-mCMV/EF1-LucSHSH was excised by 
digestion with SpeI and SfbI and exchanged for the human CMV enhancer from 
pGZCUBI [167], which was amplified by PCR with primers containing SpeI and SfbI 
sites, respectively. The pCpG-2xhCMV/EF1-LucSH was constructed by inserting a 
further PCR-amplified hCMV enhancer element, featuring PstI sites at both ends, into 
the SbfI site of pCpG-hCMV/EF1-LucSH. The orientation of this further enhancer 
element was verified by sequencing (AGOWA, Berlin, Germany).  pCpG-hCMV/EF1-
eFLuc was constructed by excision of Luc::Sh from pCpG-hCMV/EF1-LucSH by 
BglII-NehI-digestion and ligation with the BglII-AvrII-digested eFLuc sequence from 
pV2011-oFL, a kind gift from Rabinovich, M.D. Anderson Cancer Center, Houston, 
[112]. pCpG-hCMV/CMV-eFLuc was cloned by inserting the CMV promoter, cut out 
from pCMV-GLuc (New England BioLabs (NEB), Frankfurt am Main, Germany) with 
SnaBI and HindIII, into the equally digested pCpG-hCMV/EF1-eFLuc, resulting in an 
exchange of the EF-1 promoter for the CMV promoter. The synthetic promoter SCEP  
sequence was produced by Geneart (Regensburg, Germany) and cloned into the 
SpeI/HindIII digested pCpG-hCMV/EF1-eFLuc backbone, thus exchanging the EF-1 
promoter and forming the plasmid pCpG-hCMV/SCEP-eFLuc.   
The construction of the CpG-replete pEPI-1 and pEPI1∆S/MAR vector backbones, 
with the transgene EGFP under the control of the CMV-IEP, has been described 
previously [108]. The EGFP gene was exchanged for the fusion gene EGFP::Luc by 
digestion of the backbones with NehI/BglII and insertion of the PCR amplified 
EGFP::Luc sequence from pEGFPLuc (Clontech, Saint-Germaine-en-Laye, France), 
thereby using 5´ NehI and 3´ BglII primers. The resulting plasmids, pEPI1-CMV-
EGFPLuc and pEPI1∆S/MAR-CMV-EGFPLuc, were digested with PciI/NehI to 
remove the CMV-IEP and the HPGL and APOE promoter were inserted instead. All 
liver specific promoters were generated by PCR of human genomic DNA with PciI 
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and NehI primers. The resulting plasmids were: pEPI1-HPGL-EGFPLuc, pEPI1-
APOE-EGFPLuc, pEPI1∆S/MAR-HPGL-EGFPLuc and pEPI1∆S/MAR-APOE-
EGFPLuc. 
The cloning of the shuttle vector pHulk, which served as a template for all pEPito and 
pEPIto∆S/MAR based plasmids, has been described already [113]. pHulk is CpG-
depleted with a R6K ori, a zeosine resistance and β-lactamase gene, and a MCS 
(multiple cloning site). To add the EGFP::Luc gene it was amplified by PCR, as 
described above, and inserted into the NehI/BglII digested pHulk, resulting in 
pEPIto∆S/MAR-EGFPLuc. By inserting the CMV-IEP, isolated as a PciI/NehI 
fragment from pEGFP-C1 (Clontech), pEPIto∆S/MAR-CMV-EGFPLuc was created. 
The S/MAR sequence originates from pTZ-E20, from where it is cut out and ligated 
into the pEPIto∆S/MAR-CMV-EGFPLuc by EcoRI/BglII digestion, thus forming 
pEPIto-CMV-EGFPLuc. By inserting liver specific promoters, generated as described 
above, instead of the CMV-IPE (excised by PciI/NehI digestion), the plasmids 
pEPIto-AFP-EGFPLuc, pEPIto-HPGL-EGFPLuc, pEPIto-APOE-EGFPLuc and 
pEPIto-FMO-EGFPLuc were created. The human CMV enhancer from pGZCUBI was 
PCR amplified with NcoI and PciI primers and inserted into the PciI digested pEPIto-
AFP-EGFPLuc, pEPIto-HPGL-EGFPLuc and pEPIto-APOE-EGFPLuc plasmids to 
generate pEPIto-AFP/CMV-EGFPLuc, pEPIto-HPGL/CMV-EGFPLuc and pEPIto-
APOE/CMV-EGFPLuc. pEPIto-CMV-GLuc was cloned by digesting pEPIto-CMV-
EGFPLuc with NehI/BglII, thereby excising the EGFPLuc, and in its place inserting 
the GLuc sequence from pCMV-GLuc (NEB), amplified with NehI and BglII primers. 
All cloning work of plasmids was conducted by Rudolf Haase (Ludwig-Maximilians 
University, Munich). All plasmids were amplified in E. coli GT115 or DB3.1λpir, 
except for pEGFPLuc and pCMV-GLuc, which were amplified in DH5α, and isolated 
using a Qiagen (Hilden, Germany) Plasmid Giga or Maxi Prep. 
 
2.2. In vitro studies 
2.2.1. Cell lines and cell culture conditions 
Primary porcine smooth muscle cells (PSMC) were grown in Ham´s F12 (Biochrom, 
Berlin, Germany)/ Waymouth (Gibco, Darmstadt, Germany) medium 1:1, 37,5 ‰ 
sodium bicarbonate (Gibco), 0,01M HEPES, 10% bovine calf serum (FCS) (Gibco), 
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40mM stable glutamine (Biochrom), 100U/ml penicillin and 100µg/ml streptomycin 
(Biochrom), 0,25 µg/ml amphotericin B (Sigma Aldrich, Steinheim, Germany).  
Murine neuroblastoma cell line Neuro 2A (N2A, ATCC CCL-131), murine melanoma 
cell line B16F10 (kindly provided by I. J. Fidler, Texas Medical Center, Houston, TX, 
USA), human glioblastoma cell line U87MG (ATCC HTB 14), human colon carcinoma 
C26 (kindly provided by A. Anz, Klinikum der LMU, München, Germany) and the 
human cervix carcinoma cell line HeLA (ATCC CCL-2) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, 1g glucose/l (Biochrom)) completed with 10% 
FCS. U87MG was grown on collagen G (Biochrom) coated plates.  
Human hepatocellular carcinoma cell lines HuH7 (JCRB 0403, Tokyo, Japan) and 
HepG2 (kindly provided by Prof. Spitzweg, Klinikum der LMU, München) and human 
melanoma cell line MDA MB-435 (kindly provided by A. Ulrich, Max-Planck Institute, 
Munich, Germany) were cultivated in DMEM/Ham’s F-12 medium 1:1 supplemented 
with 10% FCS and 2mM stable glutamine. 
BT459, a human breast cancer cell line (CLS, #300132), Du145 (ATCC HTB-81), a 
human prostate cancer cell line, and the murine fibroblast cell line L929 (ATCC CCL-
1) were cultivated in RPMI 1640 (Biochrom) medium supplemented with 10% FCS. 
The human breast adenocarcinoma cell line MCF-7 (kindly provided by A. Ulrich, 
Max-Planck Institute, Munich, Germany) was cultured in DMEM medium (5g 
glucose/l) supplemented with 20% FCS.  
All cultured cells were grown at 37 °C in 5% CO2 humidified atmosphere. 
 
2.2.2. Isolation of primary porcine smooth muscle cells (PSMC´s) 
Porcine aortas where transported cold in PBS with antibiotics (500 U/ml penicillin, 
500 µg/ml streptomycin and an antifungal (1,25 µg/ml amphotericin B) until isolation. 
One organ was divided into 2 parts and the endothelial side was washed once with 
PBS. 5 ml of enzyme solution (0,1%, collagenase II (Sigma Aldrich) and 0,1% trypsin 
(Biochrom) diluted in PBS) was added to the aorta piece and incubated for 20 
minutes at 37°C. The enzyme solution was carefully exchanged for 5 ml M199 
medium (Biochrom). By pipetting up and down and careful scraping with the pipette 
the endothelial cells (EC´s) were detached. The medium containing the EC´s were 
collected and the scraping process was repeated several times. The collected EC´s 
were processed further for other purposes and the remaining aorta were cut into 
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small pieces (2-5 mm) for the isolation of PSMC´s. 75 cm² Corning cell culture flasks 
were filled with 10 ml PSMC isolation medium (Ham´s F12 and Waymouth medium 
1:1, 37,5 ‰ sodium bicarbonate, 0,01M HEPES, 10% FCS , 40mM L-Glutamine, 
500U/ml penicillin, 500µg/ml streptomycin, 1,25 µg/ml Amphotericin B) and the 
medium was evenly distributed in the flask. The flask was then tilted and the small 
pieces of aortas were put on the upper part of the bottle bottom, which was bare of 
medium, to allow them to stick to the bottom over night. On the following day the 
flasks were laid horizontal again, flooding the cells. The medium was exchanged 
every 2-3 days and after 2-3 weeks, when PSMC´s were growing out, the aorta 
pieces were removed and the cells splitted. After a confluence of 70-90% was 
reached, the cells were aliquoted in bovine calf serum with 10% DMSO and frozen in 
liquid nitrogen for storage. 
 
2.2.3. In vitro transfections 
General procedure (if otherwise not noted): 
Cells were seeded 24h before transfection and the cell medium was exchanged for 
fresh growth medium (with serum) directly prior transfection. Polyplexes were formed 
by rapid mixing of pDNA and the transfection reagent H DO (synthesized by Verena 
Russ, Ludwig-Maximilians University, Germany [168]) solution at a c/p (conjugate to 
plasmid) ratio of 2 in HEPES-buffered saline (HBS, 20 mM HEPES, 150 mM NaCl, 
pH 7.1) and incubated for 20 minutes at room temperature. After 4h of incubation of 
the cells with the polyplexes the medium was changed for fresh cell medium. For 
measurements the cells were trypsinised and a part thereof was lysed in 0,5x lysis 
buffer (Promega, Mannheim, Germany) and analysed by luciferase-assay. 
Transfection of MDA MB-435: 
125 000 cells were seeded in duplicates in 24-wells and were transfected with 800ng 
pDNA (pEGFPLuc, pCpG-mCMV/EF1-LucSH, pCpG-hCMV/EF1-LucSH, pCpG-
2xhCMV/EF1-LucSH). 
Transfection of PSMC´s with GLuc-plasmids: 
Cells were transfected in 2nd passage.  
Quiescent cells: PSMC´s were seeded in 6-wells (n=4) and were grown to a 
confluency of about 70 %. Then the normal growth medium was exchanged for 
medium with additional 300 µg Heparin/ ml to stop cell growth. After an incubation of 
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24h in heparin the cells were transfected with 4 µg of pDNA (pEPIto-CMV-GLuc, 
pCMV-Gluc). During transfection, medium without heparin was used, which was 
exchanged for heparin containing medium after 4h, which was then used throughout 
the experiment. Every second day medium was collected and measured for GLuc 
activity. 
Cycling cells: 100 000 cells were seeded in triplicates in 24-wells and let to grow until 
40-50% confluency before transfection with 4µg of pDNA (pEPIto-CMV-EGFPLuc, 
pEGFPLuc). 
Transfection with eFLuc-plasmids: 
10 000 HuH7, MCF-7, N2A and MDA MB-435 cells were seeded in 96-wells (n=5) 
and transfected with 200ng of pDNA (pCpG-hCMV/EF1-LucSH, pCpG-hCMV-eFLuc, 
pEPIto-CMV/AFP-EGFPLuc, pEPIto-CMV/AFP-eFLuc, pEPIto-CMV-EGFPLuc, 
pEPIto-CMV-eFLuc) and LPEI (linear polyethylenimine, synthesized in the working 
group of Prof. Wagner, Ludwig-Maximilians University, Germany) at an N/P (nitrogen 
to phosphate) ratio of 6 in HBS. 24h after transfection all cells were lysed and 
luciferase activity was measured by luciferase assay. 
Transfection with pCMV-Luc-MC and pCMV-Luc:: 
50 000 PSMC and N2A cells were seeded in triplicates in 24-wells. For transfection 
750ng pCMV-Luc-MC for PSMC´s and 500ng for N2A were used. pCMV-Luc was 
applied either with an equal pDNA weight or in equimolar amounts (PSMC:1200ng 
and N2a:795ng) compared to pCMV-Luc-MC.  
Transfection of HuH7 cells with plasmids containing liver specific promoters: 
50 000 HuH7 cells (n=2-3) were seeded into 24-wells and transfected with 1,5 µg 
pDNA. 
Transfection of pEPIto-AFP/CMV-EGFPLuc and pEPIto-CMV-EGFPLuc into different 
cell lines: 
10 000 (HuH7, Du147, N2a, U87MG, L292, HepG2) or 5000 (B16F10, BT459, C26, 
HeLa) cells were seeded in 96-wells (n=5) and transfected with 200 ng pDNA 
complexed with LPEI at an N/P ratio of 6 in HBS. 24h after transfection all cells were 
lysed and luciferase activity was measured by luciferase assay. 
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2.3. In vivo studies 
2.3.1. Hydrodynamic delivery 
6-7 weeks old female Balb/C (Elevage Janvier, Le Genest de Saint Isle, France) or 
immune deficient, hairless SHO-SCID ( Crl:SHO-PrkdcscidHrhr male and female, 
Charles River, Borchen, Germany) were rapidly injected via the tail vein with a 
volume corresponding to 10% of the body weight of Ringer-Lactate (B. Braun, 
Melsungen, Germany) solution containing 12,5 µg/ml of  pDNA using a 27-gauge 
needle. Mice were kept anaesthetised by inhalation of isoflurane (Forene, Abbott, 
Wiebaden-Delkenheim., Germany) by a gas manifold with a flow rate of 2% during 
treatment.  
All animals were given adequate care in compliance with institutional and state 
guidelines. 
 
2.3.2. Xenograft implantation and electroporation 
3 million MDA MB-435 cells in 100µl PBS were injected s.c. into each flank of SCID ( 
CB17/Icr-Prkdcscid/IcrCrl, Charles River) or hairless SCO-SCID mice. The growth of 
tumours was followed by measurements with a vernier caliper in three orthogonal 
dimensions (L × W × H, mm). When the tumours had reached an average volume of 
about 100 mm² electroporation was performed: Mice were anaesthetised by 
inhalation of isoflurane. Plasmid solution, containing 25µg pDNA diluted in 25µl 
Ringer-Lactate solution were injected i.t. Subsequently, two parallel plate electrodes 
of stainless steel (9,5 x 9,5mm), fixed on a vernier caliper, were placed on both sides 
of the tumour and four rectangular-shaped electrical pulses with amplitude of 300V, 
pulse duration of 25 ms and time interval of 100ms were delivered using the BTX 
ECM-830 Electro Square Porator (BTX Harvard Apparatus, Holliston, MA, USA). 
Good contact between the electrodes and skin was ensured by conductive gel 
(Ultraschallgel, TMP Tüshaus Medical Produkte). 
  
2.3.3. In vivo imaging 
For live examination of luciferase expression in vivo mice were anaesthetised by 
administration of isoflurane and injected i.p. with 100µl D-luciferin (60mg/ml, 
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Promega) diluted in PBS. After 10 minutes the mice were imaged for 
bioluminescence in an IVIS Lumina device (Caliper Life Sciences, Mainz, Germany) 
in a light-tight chamber on an adjustable, heat-controlled stage. Images were 
acquired at a small (hydrodynamic delivery and electroporation) or large (systemic 
administration) binning level. The acquisition time was set depending on the 
bioluminescence intensity. Data were analysed using the Xenogen Living Image 3.0 
software. 
2.3.4. Isolation of tumour cells 
The mice were sacrificed by cervical dislocation and the tumours resected. Tumor 
tissue was homogenised in 0,7ml PBS with the Medimachine system 
(DakoCytomation, Glostrup, Denmark) for 20 seconds. The cell suspension was 
sieved through a 40 µm strainer (BD Biosciences, Heidelberg, Germany) and divided 
into 2 parts. One part was lysed immediately in 1x lysis buffer and analysed by 
protein measurement and luciferase assay. The other part was taken into cell culture 
in isolation medium, containing DMEM/Ham´s F12 1:1, 10% FCS, 200 U/ml penicillin, 
200 µg/ml streptomycin, 0,25µg/ml amphotericin B and 2mM stable glutamine. The 
cells were analysed by luciferase assay continuously thereafter. 
The protein measurement was done with a BCA-kit (Thermo Scientific, Schwerte, 
Germany) according to the manufacturer’s recommendations. First, 25µl of the cell 
lysate was mixed with 5µl 0,1M iodacetamide and incubated for 30 minutes at 37°C 
to inactivate the DDT (dithiothreitol) of the lysis buffer. Then the solution was mixed 
with 200µl of working solution from the kit and incubated a second time for 30 
minutes at 37°C before the absorbance was measured at 590 nm in a plate reader 
(Spectrafluor plus, Tecan Austria GmbH, Grödig, Austria). For quantification 
purposes a standard curve of serially diluted BSA was included. 
2.4. Luciferase-assay 
2.4.1. Firefly luciferase 
Cells were trypsinised, a part thereof collected by centrifugation at 1000 rpm for 10 
minutes and consequently lysed in 0,5x lysis buffer (Promega) for 20-30 minutes at 
room temperature. Alternatively, all cells were lysed directly in the wells after removal 
of the cell medium. The lysate was measured in a tube luminometer (Lumat LB 9507, 
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Berthold Technologies, Bad Wildbad, Germany) with an integration time of 10 
seconds following a 2 seconds lag time after the injection of luciferase assay reagent 
(LAR; 20mM glycylglycine, 1 mM MgCl2, 0,1mM EDTA, 3mM DTT (Sigma-Aldrich), 
0,55mM ATP (Roche, Mannheim, Germany), 0,3mM CoA (Sigma-Aldrich), 0,5 mM D-
luciferin (Promega), pH 8,5).  
Small changes in the protocol were made for the in vivo electroporated and 
passaged tumour cells. They were lysed in 1x lysis buffer and the measurement time 
was increased to 3 minutes. 
As a control of background autofluoresence level, untransfected cells were 
measured. 
2.4.2. Gaussia luciferase 
Cell medium was spun at 300 g for 5 minutes to remove detached cells. 5µl was 
measured using the tube luminometer after injection of the coelenterazine solution 
(50mM Tris-Cl, 0,5M NaCl, 20µM coelenterazine (Synchem, Felsberg, Germany), pH 
7,8). Measurement parameter was identical as for the firefly luciferase assay (2.4.1) 
 
2.5. Q-PCR 
Livers were pulverised in liquid nitrogen using a mortar and pestle and from this total 
liver DNA was extracted using a QIAmp DNA Mini Kit (Qiagen) according to the 
manufacturer’s protocol. The DNA was concentrated by ethanol precipitation and the 
final DNA concentration was determined by photometric measurements at 260nm.  
The plasmid copy number was determined by absolute quantification using primers 
and probes complementary to the Luciferase::Sh gene (forward: 5´-
tcatgtctggctatgtgacaac-3´, reverse: 5-agccatccttgtcaatcagg-3´, probe #49 of 
Universal Probe Library, Roche). One amplification reaction of 20µl contained 
template DNA, 1x LightCycler 480 Probes Master (Roche), 200nM primers and 
100nM probe. As template 5µg of liver DNA was used. For quantification purposes a 
standard curve of serial dilutions of pDNA mixed with 5µg of liver DNA from untreated 
animals was generated. All samples were done in duplicates.  
Q-PCR was carried out with a LightCycler 480 (Roche) device with an initial heating 
at 95°C for 10min, then 40 cycles of 60°C for 30s, 72°C for 1s and 40°C for 10s. 
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Primer sequences were designed using the Universal ProbeLibrary Assay Design 
Center (https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=uplct_030000) and the 
corresponding oligonucleotides were synthesized by Eurofins MWG Operon 
(Ebersberg, Germany). 
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3. Results 
3.1. Comparison of human versus murine CMV enhancer and their 
effect on transgene expression in vivo  
Many factors can influence the stability of transgene expression in vivo, such as the 
CpG-content, the choice of promoter and enhancer, as well as the transgene itself. 
Here we wanted to investigate the effect of the enhancer sequence on the level of 
transgene expression. For this purpose we used the plasmids pCpG-hCMV/EF1-
LucSH and pCpG-mCMV/EF1-LucSH (fig. 2), which are both CpG-reduced to 
minimize immune reactions. They are carrying the transgene luciferase in the form of 
a fusion gene (LucSh), where the luciferase is fused to the bla-gene to stabilize the 
CpG-reduced luciferase. The transgene is driven by the strong, ubiquitous EF-1 
promoter. The plasmids also contain two naturally CpG-deplete S/MAR-sequences 
from the IFN-β and β-globulin gene, which are situated between the bacterial and 
mammalian expression cassette for insulation. The only differing sequence in these 2 
plasmids is the about 300 bp long enhancer, which is originating from either the 
human or murine CMV, and is located upstream of the promoter. By injecting the two 
plasmids into mice by hydrodynamic delivery and measuring the luciferase 
expression in the liver by in vivo imaging, a direct comparison of transgene 
expression duration and strength could be made between the plasmids. The method 
of hydrodynamic delivery was chosen, since it is a fast procedure to achieve well 
measurable transgene signals without possible disturbing effects from a carrier 
system.  
The luciferase signals from the two plasmids are showing approximately the same 
level of activity  after injection and remain relatively stable the first two weeks (except 
for a minor drop in signal at day 5 after injection in the case of  pCpG-mCMV/EF1-
LucSH) (fig. 3). After this 14-day plateau in signal strength, an abrupt drop in 
luciferase expression is observed. After another week the signals are somewhat 
stabilizing in both cases, leading to a persistent and still strong signal from pCpG-
hCMV/EF1-LucSH, which remains for over 100 days post administration, whereas 
the signal of pCpG-mCMV/EF1-LucSH is gradually decreasing, resulting in a total 
loss of transgene signal at day 43 after plasmid injection  
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Fig. 2: Plasmid map of the CpG-free pCpG-hCMV/EF1-LucSH, pCpG-mCMV/EF1-LucSH and 
pCpG-2xhCMV/EF1-LucSH and CpG-replete pEGFPLuc plasmid. Scaffold matrix attachment 
region of 5´-region of the human IFN- β (IFN-β S/MAR) and β-globulin (β–Glo S/MAR) genes, 
which are naturally CpG-free sequences; R6K ori from E. coli for propagation in bacteria having 
the pir gene, expressing the initiator protein π ; Zeo, zeocin resistance gene for antibiotic 
selection, driven by the E2MK promoter (CpG-free version of bacterial EM7 promoter); hCMV enh 
and mCMV enh, enhancer from either human or murine cytomegalovirus; hEF1 prom, core 
promoter and 5´UTR of human elongation factor 1 alpha gene; Luc::SH, fusion gene of CpG-free 
firefly luciferase and Sh bla gene, the latter conferring zeocin resistance; SV40 polyA, late 
polyadenylation signal from simian virus 40; CMV-IEP, human cytomegalovirus immediate early 
promoter and enhancer; EGFP::Luc, fusion gene of enhanced fluorescent protein and firefly 
luciferase; Kan/Neo, neomycin phosphotransferase gene, rendering kanamycin and neomycin 
resistance, driven by SV40 promoter and bacterial promoter; HSV-tk polyA, herpes simplex virus 
thymidine kinase polyadenylation signal;  pUC ori, pUC plasmid replication ori 
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Fig. 3: Transgene expression in liver of Balb/C mice treated with naked plasmid DNA by 
hydrodynamic delivery.  Luciferase activity was measured by in vivo imaging. pCpG-
hCMV/EF1-LucSH:SH n=8, pCpG-mCMV/EF1-LucSHSH: n=10. At day 37 half of the mice 
were sacrificed for DNA-isolation of liver cells. p/s: photons/second. 
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Fig. 4: Plasmid copy number in liver tissue 37 days after hydrodynamic delivery. Total 
DNA was investigated by QPCR. A standard curve of plasmid DNA allowed for quantification 
of the plasmid number in the liver (4A, left). The plasmid number was plotted against the 
transgene signal (4B, right). p/s: photons/second. *p<0,05, t-test 
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To determine if this difference in transgene signal level and endurance also was 
manifesting itself in the plasmid copy number, an absolute quantification by QPCR.  
was made from total DNA isolated from liver tissue at day 37 after hydrodynamic  
injection.  The result in fig. 4A shows a 4-fold higher mean plasmid copy number in  
the group treated with pCpG-hCMV/EF1-LucSH compared with the group of pCpG-
mCMV/EF1-LucSH. When the plasmid copy number was plotted against the 
luciferase signal (fig. 4B) an almost linear correlation is produced. Hence, there is a 
connection between high transgene expression and plasmid retention, and they are 
both positively influenced by the human CMV-enhancer, when compared with the 
murine counterpart. 
 
The human and murine enhancers have evolutionary been optimized to fit to their 
respective host cells, resulting in different design. They are both containing 
numerous binding sites for transcription factors in different compositions. The human 
CMV-enhancer is in total having more transcription factor binding sites than the 
murine, leading to the assumption that this could be contributing to the differences in 
expression between pCpG-hCMV/EF1-LucSHSH and pCpG-mCMV/EF1-LucSHSH. 
To examine this, a second human CMV-enhancer was inserted into pCpG-
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Fig. 5: Effect of tandem hCMV enhancer sequence (pCpG-2xhCMV/EF1-LucSH) on 
transgene expression in vivo, compared to single sequence (pCpG-hCMV/EF1-LucSH). 
Luciferase activity in liver was measured by in vivo imaging after hydrodynamic delivery of naked 
pDNA in Balb/C mice. pCpG-2xhCMV/EF1-LucSH; n=6, pCpG-hCMV/EF1-LucSH; n=4, p/s= 
photons per second. 
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hCMV/EF1-LucSHSH, resulting in a tandem repeat of the sequence. The final 
construct, pCpG-2xhCMV/EF1-LucSHSH, (fig. 2) was then compared with pCpG-
hCMV/EF1-LucSH by hydrodynamic injection into mice and consequent 
measurement of liver expression.  
 
The first two weeks after injection the pCpG-hCMV/EF1-LucSH is showing a higher 
expression when compared to pCpG-2xhCMV/EF1-LucSH, but the signal from both 
plasmids is rather stable (fig. 5). Then CpG-hCMV-Luc is experiencing the strong 
decrease in signal strength, as already observed (fig. 3), whereas the pCpG-
2xhCMV/EF1-LucSH is having a somewhat delayed drop. 3 weeks after injection, the 
transgene expression from both plasmids is equal strong and stays stable at this 
level for an extended period of time. So the introduction of a second human CMV-
enhancer is extending the signal but does not lead to a stronger transgene 
expression. 
 
3.2. Influence of immune status on transgene expression in vivo 
The rather stable luciferase signal in the beginning, followed by the rapid decrease 
over several log-units of pCpG-mCMV/EF1-LucSH and pCpG-hCMV/EF1-LucSH in 
fig. 3 is greatly differing from the expression profile of the commercially available 
plasmid pEGFPLuc in fig. 6, where it was compared with the pCpG-mCMV/EF1-
LucSH by injection into mice by the hydrodynamic method. This led us to the 
question, as to what caused the characteristic expression-over-time profile of pCpG-
hCMV/EF1-LucSH and pCpG-mCMV/EF1-LucSH. To investigate if the sudden drop 
around day 14 after plasmid injection could be due to immunological reactions, the 
plasmids pCpG-hCMV/EF1-LucSH, pCpG-mCMV/EF1-LucSH, pCpG-2xhCMV/EF1-
LucSH and pEGFPLuc were injected by hydrodynamic delivery into immunodeficient 
SCID mice, lacking functional B- and T-cells. The plasmid pEGFPLuc (fig. 2) is, in 
comparison to the other plasmids used, CpG-replete and its transgene, a fusion of 
luciferase and EGFP, is driven by a CMV-promoter.  
The results show that the expression profile of pEGFPLuc is very similar in 
immunocompetent (fig. 6) and –deficient (fig. 7) mice, where in both cases the signal 
is drastically reduced within 2 weeks. This reduction could in both cases be due to 
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Fig. 6: Comparison of CpG-replete, CMV-promoter driven (pEGFPLuc) with CpG-
deplete, EF1-promoter driven (pCpG-mCMV/EF1-LucSH) luciferase expression in liver 
of Balb/C mice. Plasmids were injected by hydrodynamic delivery and luciferase signal was 
measured by in vivo imaging. pEGFPLuc; n=4, pCpG-mCMV/EF1-LucSH; n=6. Data was 
generated by Nicole Tietze. 
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Fig. 7: Comparison of CpG-deplete, EF1-promoter driven plasmids (pCpG-mCMV/EF1-
LucSH, pCpG-hCMV/EF1-LucSH and pCpG-2xhCMV/EF1-LucSH) and CpG-replete, CMV-
promoter driven plasmid (pEGFPLuc) in immune deficient mice. Plasmids were injected by 
hydrodynamic delivery into SCID mice and the transgene expression was followed by in vivo 
bioluminescence measurements. n=4 (pCpG-mCMV/EF1-LucSH, pCpG-2xhCMV/EF1-LucSH), 
n=5 (pCpG-hCMV/EF1-LucSH, pEGFPLuc) 
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he already reported fast CMV-promoter inactivation by methylation [26, 27]- The EF-
1 driven plasmids, pCpG-hCMV/EF1-LucSH, pCpG-mCMV/EF1-LucSH and pCpG-
2xhCMV/EF1-LucSH, rendered very stable and high expression in the 
immunodeficient SCID mice (fig. 7), and there was no sudden reduction in transgene 
signal, as in the case of the immunocompetent Balb/C mice (fig. 3 and 5). Therefore, 
one can assume, that the host adaptive immune system is causing the fast reduction 
in transgene signal two weeks after injection. 
 
3.3. Plasmid retention in a tumour model 
After having seen the advantages of the hCMV versus the mCMV enhancer on the 
transgene expression in the liver, we were investigating if this is also the case in a 
xenograft model of human tumor in SCID mice.The human melanoma cell line MDA 
MB-435, which we know from previous work is forming slow growing tumours, was 
selected to allow monitoring of the transgene expression over a sufficiently long time 
period. 
After inoculation of the tumour cells s.c. into immune deprived SCID mice the 
plasmids pCpG-hCMV/EF1-LucSH, pCpG-mCMV/EF1-LucSH, pCpG-2xhCMV/EF1-
LucSH and pEGFPLuc were electroporated i.t. when tumours had reached a 
palpable size. Afterwards, the luciferase expression of the plasmids was measured 
continuously by in vivo bioluminescence measurements.  
As seen in fig. 8 the expression in the tumour does not change considerably over 
time and is 25 days after electroporation at more or less the same level as at day 
one. This matches the expression in the liver of immune deficient mice (fig. 7). In 
contrast to liver transfection, the plasmid pEGFPLuc also gives a stable signal in 
tumor tissue, although its signal in the liver is decreasing over time (fig. 6 and 7). 
To see if the persistent gene expression would remain when the tumour cells were 
taken out of the in vivo surroundings the experiment was repeated, this time only with 
pCpG-hCMV/EF1-LucSH. At day one and day 27 after electroporation tumours were 
resected and the tumour cells taken into cell culture. A luciferase gene expression 
assay was performed at the day of isolation and again after 10 and 15 
days.
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Again, the luciferase expression stayed relatively stable over time in the 
subcutaneous tumour (fig. 9A). When the cells were removed from the animal, the 
luciferase expression in cell culture  was reduced to background levels within 2 
weeks, no matter if the cells were isolated from the mouse on day 1 (fig. 9B) or day 
27 (fig. 9C) after electroporation. MDA MB-435 cells were also transfected in vitro 
with a polyplex formulation. The luciferase activity was continuously measured by 
luciferase assays and the result is displayed in fig. 10. Similar as in the reisolated 
cells, the transgene signal is lost 2 weeks post transfection. This fast loss of 
transgene signal in vitro and the stable signal in vivo could be explained with the 
higher cell growth in  
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Fig. 8: Transgene expression in a subcutaneous tumour model. Naked plasmid DNA was 
delivered into subcutaneous MDA MB-435 tumours in SCID mice by electroporation. The 
luciferase signal was monitored thereafter by in vivo imaging (A) and the tumour growth by 
calliper measurements (B). n=8 tumours per group. 
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the cell culture. Growing freely in the flask the cells would have undergone 
approximately 10-14 cell divisions in the 2 weeks of culture (doubling time~24h, but 
the reisolated cells were growing slower in the time directly after isolation). The 
tumour cells were growing slower in vivo; tumour volume increased from 125mm³ to 
about 500mm³ from day 1 to day 27 after electroporation (fig. 8B). This could 
correlate to two cell divisions or slightly more, since MDA MB-435 forms compact, 
hard tumours. 
So loss of pDNA seems to be tightly associated with cell division. This was also 
investigated in an experiment where cells were transfected with 
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Fig. 9: Transgene expression in vivo and in vitro. (A) pCpG-hCMV/EF1-LucSH was injected 
into subcutaneous MDA MB-435 tumours and subsequently electroporated. Luciferase expression 
in the tumours was measured by in vivo imaging and the values were normalised on the day one 
value. On the first day after electroporation half of the mice were sacrificed and tumour cells were 
isolated and taken into cell culture. A luciferase assay was performed on the day of cell isolation 
(d1), as well as on day 10 and 15. (B). On day 27 after electroporation the rest of the mice were 
sacrificed and the procedure was repeated (C). n=10 tumours in total. RLU: relative light units. 
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luciferase expressing plasmids and then either let to grow without restrains or 
stopped in their proliferation. For this, primary porcine smooth muscle cells (PSMC´s) 
were used because they are known to be inhibited by treatment with heparin [114, 
115]. For the growth inhibition assay the cells were transfected with the plasmids 
pEPIto-CMV-GLuc and pCMV-GLuc (fig. 11A, C), both carrying the gene for the 
naturally secreted luciferase from the marine copepod Gaussia princeps (GLuc), 
enabling a luciferase measurement of the secreted luciferase in the medium without 
disturbing the cells. The transgene is in both plasmids driven by a CMV-promoter and 
in the pEPIto-CMV-Gluc the luciferase gene is followed by an S/MAR-sequence. 
Directly after transfection heparin was added to the cell medium to stop cell growth 
and cell medium was continuously collected to be analysed by luciferase assay. The 
result is seen in fig. 11D: The expression stays relatively stable over 1 month time.   
As a comparison to the growth arrest assay PSMC´s were let to grow with no 
restrictions. They were transfected with the plasmids pEPIto-CMV-EGFPLuc (fig. 
11B) and pEGFPLuc (fig. 2), both expressing an EGFP-Luc fusion protein. Also 
here, the expression is driven by a CMV-promoter and an S/MAR-sequence had 
been introduced behind the transgene in the pEPIto-CMV-EGFPLuc. The expression  
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Fig. 10: In vitro transfection of MDA MB-435 cells with pDNA complexed with H DO. Luciferase 
assays were done continuously thereafter to monitor transgene expression. Background level was 
deducted from signals. RLU: relative light units. 
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Fig. 11: Transgene expression in primary PSMC´s after transfection with plasmids pEPIto-
CMV-Gluc (A), pEPIto-CMV-EGFPLuc (B), pCMV-Luc (C) and pEGFPLuc, with (D) or without 
(E) growth inhibition. (A)-(C): R6K ori from E. coli for propagation in bacteria containing the pir 
gene, expressing the initiator protein π; Zeo, zeocin resistance gene; CMV-IEP, human 
cytomegalovirus immediate early promoter and enhancer region; GLuc; Gaussia luciferase; IFN-β 
S/MAR, scaffold matrix attachment region of the human interferon-β gene, Amp, ampicillin 
resistance gene, Neo, neomycin resistance gene, SV40 prom, simian virus 40 promoter, CMV 
prom, cytomegalovirus promoter; Ori, origin of replication; EGFP::Luc fusion gene of  enhanced 
green fluorescent protein and Firefly luciferase. (D): PSMC`s were transfected and then treated 
with heparin to stop proliferation. Luciferase activity was continuously measured in the 
supernatant. n=4 (E): Transfection of PSMC under normal growth conditions (without heparin). 
n=3. Background signal is deducted from measured values. 
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 over time was observed by lysing a part of the cell population and performing 
luciferase assays on the lysate. In this case the expression is rapidly decreasing (fig. 
11E) and has reached the background level within 3 weeks. Hence, the plasmids are 
lost when the cells are dividing freely, as shown with the PSMC and MDAMB-435 
cells in culture, and are retained when the cells are in a slow growing-status, as in 
the MDA MB-435 tumour or the heparin treated PSMC´s. 
 
3.4. Evaluation of a novel synthetic promoter, SCEP, in vivo  
The two promoters used so far, the CMV-IEP and EF-1 both render ubiquitous 
transgene expression, but they are not optimal and have both pros as well as cons: 
the CMV-IEP is generally stronger than the EF-1, but is of viral origin, whereas the 
EF-1 is derived from mammalian DNA. CMV-IEP undergoes promoter methylation 
shortly after nuclear entry, a phenomenon which does not occur in the case of EF-1. 
Our idea was to combine these two promoters to take advantage of the 
transcriptional strength of the CMV-IEP and the transcriptional stability of the EF-1 to 
create a novel, ameliorated promoter. By identifying homologous regions between 
the 2 sequences and combining these to a new optimized promoter for strong 
expression and binding of transcriptionally strong transcription factors, as tested by 
various programs, the CpG-free promoter SCEP was created. SCEP stands for 
shuffled CMV EF-1 promoter. For in vivo testing of the novel promoter, plasmids 
were cloned on the basis of the CpG-reduced pCpG-hCMV/EF1-LucSH (fig. 2). First, 
the transgene Luc::Sh was exchanged for an enhanced firefly luciferase (eFLuc) 
gene, which has previously been created by codon optimisation, removal of cryptic 
splicing sites and retroviral optimisation of the firefly luciferase [112]. By introducing 
the novel transgene, forming the plasmid pCpG-hCMV/EF1-eFLuc, the resulting 
luciferase signals were clearly enhanced when comparing to the original plasmid 
pCpG-hCMV/EF1-LucSH in vitro (fig. 12). The second step was to replace the EF-1 
promoter with the SCEP or CMV promoter to create pCpG-hCMV/SCEP-efFLuc and 
pCpG-hCMV/CMV-eFLuc, respectively. As a result, all 3 plasmids have the same 
CpG-depleted backbone with the enhanced firefly luciferase as a transgene. They 
were introduced by hydrodynamic delivery into Balb/C mice and the transgene 
expression in the liver was measured by in vivo imaging. The result is shown in fig. 
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13. The new promoter SCEP renders a higher transgene expression than the EF-1 
promoter, but their expression profiles follows the same pattern, with a drop of signal 
strength at around 2 weeks after treatment, which previously could be seen with the 
EF-1 promoter containing plasmids pCpG-mCMV/EF1-LucSH and pCpG-hCMV/EF1-
LucSH (fig. 3) This time also the SCEP promoter is affected; hence, this delayed 
effect is not specific for the EF-1 promoter.  
The signal from pCpG-hCMV/CMV-eFLuc is rapidly decreased, in compliance with 
the observed silencing of the CMV-IEP [26, 27] and is then stabilized. After the drop 
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Fig. 12: In vitro comparison of enhanced firefly luciferase, eFLuc, with fusion protein 
LucSH in different cell lines. The cell lines MDA MB-435 (human melanoma), N2A (murine 
neuroblastoma), MCF-7 (human breast cancer) and HuH7 (human hepatoma) were transfected 
with polyplexes formed by condensation of pDNA and LPEI. Transgene expression was 
measured by luciferase assay 24h post transfection. The plasmids used are both CpG-reduced 
and express its transgene under the control of an EF-1 promoter and a human CMV enhancer. 
n=5, RLU: relative light units. 
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of signal from the pCpG-hCMV/EF1-eFLuc and pCpG-hCMV/SCEP-eFLuc plasmid, 
the signal of pCpG-hCMV/CMV-eFLuc is clearly superior. Thus, the drop in signal 
caused by the immune system in the case of the EF-1 and, probably also, the SCEP 
promoter had a greater impact on transgene signal than the silencing by methylation 
in the case of the CMV promoter. 
 
 
3.5. Comparison of minicircles with full-length plasmid  
In the search for an optimal vector for gene therapy results have shown that the 
covalent binding of bacterial DNA to a mammalian expression cassette can 
significantly reduce transgene expression [116]. Since the bacterial backbone is 
indispensable for the propagation in bacteria it was sought to eliminate this sequence 
post propagation, thus forming a minicircle devoid of bacterial sequences [35]. Much 
work has been investigated on developing methods to improve the efficiency of 
minicircle production [29-31, 34-38, 117], which was the major bottleneck so far. 
Another general problem occurring when isolating plasmids from bacteria is the 
relatively high amount of co-isolated bacterial DNA, which can elicit an immunologic 
response. To circumvent this, and also to increase the minicircle production 
efficiency for large-scale production, a new method was generated by the company 
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Fig. 13: Comparison of CMV, EF-1 and synthetic SCEP promoter in vivo. All plasmids are 
CpG-reduced with an hCMV enhancer and the enhanced firefly luciferase (eFLuc) as a reporter 
gene. Luciferase expression was measured by in vivo imaging after hydrodynamic delivery of the 
naked plasmids into Balb/C mice. n=6. p/s: photons per second. 
3 Results  40 
 
PlasmidFactory (Bielefeld, Germany), our minicircle provider: Recombination was 
performed by the highly efficient ParA resolvase (recombination efficiency >99,5 %), 
inducible by arabinose, followed by an affinity chromatography purification step of the 
minicircle [117]. For the purification serially arranged lactose operator (lacOs) sites 
were incorporated in the minicircle part of the parental plasmid. After arabinose 
induced recombination, the lacOs will reversible bind the minicircle to repressor of 
the lactose operon (lacI), which has been covalently bound to the solid phase of the 
chromatography. This allows for the separation of minicircle from unwanted side 
products, such as miniplasmid, parental plasmid, bacterial DNA and endotoxins, 
resulting in a purity of >98,5%. 
For biological testing one model minicircle was generated, pCMV-Luc-MC. It contains 
the CMV promoter, the luciferase gene as a transgene and is devoid of the bacterial 
expression cassette. To evaluate the minicircle in vitro, it was transfected into the 
murine tumor cell line N2A as well as into primary cells (PSMC). As a control, the full-
length paternal plasmid, pCMV-Luc, was used. The transfection was conducted with 
equal weights of plasmid DNA as well as equimolar amounts, to adjust for the lower 
molecular weight of pCMV-Luc-MC. The result is depicted in fig. 14. The long-term 
expression profile from minicircle and plasmid are not differing in N2A cells. Only in 
the PSMC´s there is an advantage of the minicircle compared to its parental plasmid. 
These results were in both cell types independent of the amount of used 
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Fig. 14: In vitro testing of the minicircle, pCMV-Luc-MC, and its corresponding plasmid, 
pCMV-Luc. N2A and PSMC cells were transfected with pDNA complexed with H DO, either in 
equal weight to weight ratio (w/w 1:1) or in equimolar amounts (mol 1:1). Luciferase expression 
was monitored by continuous luciferase assays. RLU: relative light units. n=3.  
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pCMV-Luc. This indicates that the positive effect of removing the bacterial backbone 
is, in vitro at least, cell type dependent.  
 
Since the effect of the bacterial backbone has been associated primarily to its 
unmethylated CpG´s and their interaction with the immune system, we tested the 
plasmids in immunocompetent Balb/C mice. 
 
The resulting expression-over-time graph is shown in fig. 15. The transgene 
expression from pCMV-Luc is slightly lower than from pCMV-Luc-MC, pointing to the 
negative effect of the bacterial backbone in pCMV-Luc. Like in the in vitro data, the 
amount of injected pCMV-Luc-MC compared to pCMV-Luc, equimolar or equal 
weight ratio, was not important for the relative signal strength. In this case it probably 
depends on the injection method: With the hydrodynamic delivery a plateau of 
maximal expression with high amounts of plasmids is reached, which can not be 
increased further with more pDNA [118]. Because of this we decreased the amounts 
of injected plasmid amount to reach a state of non-saturation, where the differences 
in transgene signal between minicircle and plasmid might be better detectable. For 
this experiment only equimolar amounts of plasmids were used. 
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Fig. 15: Expression in liver from minicircle pCMVLuc-MC and its corresponding plasmid 
pCMVLuc. Plasmid DNA was injected into Balb/C mice by hydrodynamic delivery and 
transgene expression was assayed by in vivo bioluminescence measurement. pCMVLuc-MC 
was applied either in a w/w ratio of 1 (12,5µ g/ml) or in equimolar ratio (7,8µg/ml) compared to 
the pCMVLuc. n=4. p/s: photons per second. 
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By decreasing the amount of plasmid (fig. 16) the transgene signals also generally 
decrease, but so does also the difference between mini- and plasmid. The highest 
difference is still seen with the first tested, highest plasmid concentration. 
 
 
3.6. Transcriptional targeting with liver specific promoters 
In order to keep gene therapy side effects low, it is in many cases important to 
achieve a locally restricted transgene expression. This restriction can be achieved on 
the level of gene delivery, where the gene delivery vehicle, provided with a targeting 
function, will direct the gene cargo to the target cells, avoiding off-target tissue. 
Additionally, or alternatively, the transgene expression itself can be restricted to 
specific organs by means of transcriptional targeting by using a tissue specific 
promoter. To investigate promoters for transcriptional targeting of the liver, different 
plasmids were designed (fig. 17): The core promoters from the liver specific genes 
FMO (flavin-containing monooxygenase), AFP (alpha-fetoprotein), APOE   
(apolipoprotein E) and HPGL (haptoglobin) were incorporated into a S/MAR- 
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Fig. 16: Expression in liver from minicircle (pCMV-Luc-MC) and full plasmid (pCMV-Luc).  
pDNA was injected by hydrodynamic method into mice in 3 different concentrations (high 
concentration: black, middle: red, low: blue) with paired equimolar amounts of pCMV-Luc (filled 
symbols) and pCMV-Luc-MC (outlined symbols). Luciferase activity in the livers was measured by 
in vivo imaging. n=5. p/s: photons per second. 
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containing CpG-reduced backbone (pEPIto) containing a fusion of luciferase and 
EGFP as a transgene, directly followed by an S/MAR sequence (pEPIto-x-EGFPLuc; 
x=promoter) (fig. 17). As a control, the CMV-promoter was used, with the plasmid 
backbone either containing the S/MAR (pEPIto-CMV-EGFPLuc) or lacking it 
(pEPIto∆S/MAR-CMV-EGFPLuc). 
For comparing the liver specific promoters with the CMV-promoter the above 
mentioned plasmids were transfected into the hepatocellular carcinoma (HCC) cell 
line HuH7 and the transgene expression strength and duration was monitored by 
luciferase assays. As expected (the CMV promoter is one of the strongest promoters 
used commercially), the plasmids with the tissue specific promoters showed a lower 
transgene expression than the pEPIto-CMV-EGFPLuc and pEPIto∆S/MAR-CMV-
EGFPLuc plasmids (fig. 18). The promoter of the FMO gene was the weakest 
promoter, with a 10-fold lower transgene expression compared to the other tissue 
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Fig. 17: Plasmid maps of CpG-reduced vectors (pEPIto). For selection purposes the gene for 
ampicillin resistance, Amp, in bacteria and zeocin resistance, Zeo, in mammalian cells were 
inserted. The R6K ori from E. coli serves the propagation in bacteria containing the pir gene, 
expressing the initiator protein π. The transgene is a fusion gene of the firefly luciferase and the 
EGFP gene, EGFP::Luc, which is driven by an promoter x; either the ubiquitously expressing 
CMV-IEP (human cytomegalovirus immediate early promoter and enhancer region) or the liver 
specific promoters HPGL (haptoglobin), AFP (alpha-fetoprotein), FMO (flavin-containing 
monooxygenase) or APOE (apolipoprotein). (A) The transgene is followed by a 2 kb scaffold 
matrix attachment region (S/MAR) from the 5´-region of the human IFN- β. (B) A CMV-promoter 
driven plasmid without the S/MAR sequence; pEPIto∆S/MAR-CMV-EGFPLuc. 
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specific promoters. After only 5 days after transfection, the luciferase signal of the 
cells transfected with pEPIto-FMO-EGFPLuc was undetectable, 
whereas the signal from the other plasmids lasted about 2 weeks. The signal loss is 
presumably primarily due to the fast cell growth in vitro, as discussed in 4.4. To test 
the persistence of the plasmids we therefore decided to use the hydrodynamic 
delivery method to measure the expression in mouse livers, since the proliferation 
rate in the liver is very low (only 1 of 20 000 hepatocytes in the adult liver is cycling 
[119]).  
Due to its low signal we excluded the pEPIto-FMO-EGFPLuc from further 
examinations. Also the pEPIto-AFP-EGFPLuc is not suitable for this set-up, since 
AFP is mainly expressed in foetal liver or liver carcinomas. The remaining plasmids 
with liver specific promoters, the pEPIto-HPGL-EGFPLuc and pEPIto-APOE-
EGFPLuc, had similar expression levels in vitro. To decide which promoter to use for 
the in vivo experiment, a small pilot study with 4 animals comparing the HPGL and 
APOE promoter was conducted,. For this purpose a CpG-replete plasmid series 
(pEPI-1) with control plasmids without S/MAR´s was utilised. The plasmids pEPI-1-
HPGL-EGFPLuc and pEPI-1-APOE-EGFPLuc (with S/MAR) and pEPI1∆S/MAR-
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Fig. 18: Luciferase activity of transfected HuH7 cells. Transfection was performed with pDNA 
complexed with H DO and the transgene expression was continuously examined by luciferase 
assays. Auto-fluorescence of untransfected cells (background) was deducted. RLU: relative light 
units. n=2. 
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HPGL-EGFPLuc and pEPI-1∆S/MAR-APOE-EGFPLuc (without S/MAR) were 
injected into mice by the hydrodynamic method. 
As seen in fig. 19 the plasmids with the HPGL promoter are superior to the vectors 
with the APOE promoter, independent on the presence of the S/MAR. Based on this  
we decided to proceed with the HPGL promoter. Aside from pEPIto-HPGL-EGFPLuc 
also pEPI1-HPGL-EGFPLuc and pEPI1∆S/MAR-HPGL-EGFPLuc were included to 
examine the long-term effect of a CpG-containing backbone and additional S/MAR-
depletion on the transgene expression. As a control pEPIto-CMV-EGFPLuc was 
used. The pDNA was injected into mice by hydrodynamic delivery and monitored 
over time by live bioluminescence measurements. 
The result from the comparison of the HPGL and CMV promoter is shown in fig. 20. 
Similar to the data presented in fig. 6 and 7, the signal from the CMV-driven plasmid 
decreases rapidly and thereafter stabilised. The signals from the plasmids with the 
HPGL promoter are following a similar pattern, but are generally one log-unit weaker 
than the signal from pEPIto-CMV-EGFPLuc. The CpG´s in the plasmid sequence of 
pEPI-1-HPGL-EGFPLuc and the additional removal of the S/MAR sequence in 
pEPI1∆S/MAR-HPGL-EGFPLuc tend to decrease expression incrementally, but the 
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Fig. 19: Comparison of plasmids with the liver specific promoters HPGL and APOE in vivo.  
The plasmids pEPI1-HPGL-EGFPLuc and pEPI1-APOE-EGFPLuc (with S/MAR) and 
pEPI1∆S/MAR-HPGL-EGFPLuc and pEPI1∆S/MAR-APOE-EGFPLuc (without S/MAR), all CpG-
replete, were injected by hydrodynamic delivery into Balb/C mice. 24h after treatment the 
luciferase activity was measured by in vivo bioluminescence imaging. n=1. p/s: photons per 
second. 
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Fig. 20: Comparative in vivo study of plasmids with liver specific HPGL promoter or 
ubiquitous CMV-promoter. Plasmid DNA was injected into Balb/C mice by hydrodynamic 
delivery method and luciferase expression was monitored by in vivo imaging. pEPI1: CpG-replete 
plasmid series, pEPIto: CpG-deplete plasmid series. n=5 (pEPI1∆S/MAR-HPGL-EGFPLuc), n=4 
(pEPIto-HPGL-EGFPLuc, pEPI1-HPGL-EGFPLuc, pEPIto-CMV-EGFPLuc). p/s: photons per 
second. 
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Fig. 21: Introduction of hCMV enhancer into plasmids bearing liver specific promoters 
enhances expression. HuH7 cells were transfected with pDNA complexed with H DO and 
transgene expression was evaluated by luciferase assay 24h post transfection. RLU: relative light 
units.  
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differences are small. With the aim to increase the expression level from the 
plasmids with liver specific promoters an enhancer from the hCMV was inserted 
upstream of the promoter. The resulting plasmids, pEPIto-hCMV/HPGL-EGFPLuc, 
pEPIto-hCMV/AFP-EGFPLuc and pEPIto-hCMV/APOE-EGFPLuc were tested by in 
vitro transfection of HuH7 cells (fig. 21). In all cases the CMV enhancer was able to 
increase the transgene expression and the highest expression was achieved with the 
plasmid pEPIto-hCMV/AFP-EGFPLuc, rendering a luciferase activity about 1 log-unit 
below the signal from pEPIto-CMV-EGFPLuc. Hence, the signal from pEPIto-
hCMV/AFP-EGFPLuc is still lower, but in the context of a gene therapy vector, this 
could be counterbalanced with a tissue specificity, which the pEPIto-CMV-EGFPLuc 
does not exhibit. To test how well defined this tissue specific expression, e.g. the 
“leakiness”, of the plasmids is, the plasmids were transfected into different cell lines 
(fig. 22). In all cases, except for in the HCC cell lines, HuH7, HepG2, and the AFP-
producing MCF-7 cell line, the signal from the pEPIto-hCMV/AFP-EGFPLuc was 
close to the background, showing a low off-target expression, whereas the pEPIto-
CMV-EGFPLuc exhibited a ubiquitous expression. 
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Fig. 22: Transfection of various cell lines with the plasmids pEPIto-CMV-EGFPLuc and 
pPEIto-hCMV/AFP-EGFPLuc, driven by the CMV-IEP and AFP-promoter/hCMV-enhancer 
hybrid, respectively. pDNA was condensed with LPEI in HBS for polyplex formation. Transgene 
expression was assayed 24h after transfection by luciferase activity measurements. RLU: relative 
light units. Control: untransfected cells. 
4 Discussion  48 
 
4. Discussion 
4.1. Human CMV enhancer leads to higher expression and better 
plasmid retention than murine CMV enhancer 
For an optimal gene therapy treatment the duration and strength of gene expression 
is of major importance. It dictates how often the treatment has to be performed and 
how much from the therapeutics you need to apply. Ideally, only a single treatment 
would be necessary, thus avoiding repetitive applications. This is especially desirable 
if the therapy is complicated, associated with physical discomfort or expensive. It is 
also worthwhile to reduce the dosis of the used therapeutics, to lower costs and 
possible side effects.  
There are many ways to increase the stability and strength of transgene expression. 
Amongst others, the choice of a good enhancer is crucial, since it can influence the 
transcription from the core promoter in a decisive fashion. It has been reported, for 
example, that the deletion of the enhancer in the otherwise intact murine CMV 
caused severe deficiencies in virus production [120]. In this study we have compared 
the enhancer from murine and human CMV and their ability to drive efficient 
expression from a luciferase expressing plasmid. 
The sequence of the CMV enhancer is only about 300 bp long in pCpG-hCMV/EF1-
LucSH and pCpG-mCMV/EF1-LucSH, containing the human and murine CMV 
enhancer, respectively, and comprises therefore only 6 % of the total plasmid DNA 
mass. It is the only differing sequence between the two plasmids, but despite its size, 
it has a great impact on the transgene expression. We could show that the 
expression from pCpG-hCMV/EF1-LucSH is clearly enhanced and prolonged in 
mouse liver when compared with the pCpG-mCMV/EF1-LucSH (fig. 3). In agreement 
with this Hyde et al [69] could show an extended transgene expression when 
replacing the murine CMV enhancer with the human counterpart in an EF1-driven 
plasmid and applying the plasmid DNA in a lipid formulation nebulised to the lung.  
Why the human CMV enhancer is working better in mouse cells is not clear yet, but 
one possible explanation could be a better enhancer-promoter interaction between 
the hCMV enhancer and the EF-1 promoter compared with the mCMV enhancer. 
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Since experimenting with Drosophila gene expression starting in 1994 the concept of 
enhancer-promoter specificity is known [17, 18], and by now it is clear that some 
enhancers exhibit a strong preference [13, 14], or even specificity [14, 16] when it 
comes to activation of the core promoters. The activation of the promoter by the 
enhancer can occur over several kb distance [121] and it is postulated that a loop is 
formed to bring the promoter and enhancer in close proximity [9, 10, 122], where a 
protein-protein interaction between bound transcription factors on the enhancer 
interacts with the promoter/transcription initiation complex to facilitate its assembly 
and transcription initiation [123]. In this scenario, it can be easily imagined that the 
nature of the enhancer bound transcription factors and the resulting enhanceosome 
complex should have a decisive role in the activation of the transcription from the EF-
1 promoter. The murine and human CMV enhancer sequences in the plasmids are 
akin with 38% sequence similarity and they are sharing about 50% of the 
transcription factor binding site types.  The remaining binding sites are differing 
between the 2 enhancers, and with binding of different transcription factors the EF-1 
promoter could be activated in a variable way. Looking at the different expression 
profile caused by the murine and human CMV enhancers, there is possibly a greater 
enhancer-promoter preference between the EF-1 promoter and the hCMV enhancer 
than the mCMV enhancer. 
The difference between the pCpG-hCMV/EF1-LucSH and pCpG-mCMV/EF1-LucSH 
is also reflected in the plasmid copy number (fig. 4), where a higher copy number is 
coinciding with a higher transgene expression. There is basically no reason why the 
pCpG-hCMV/EF1-LucSH should have a better retention potential when just looking 
at the plasmid sequence, since they are almost the same, except for the enhancer. 
Therefore, the better retention potential must derive from the enhancer itself; or more 
specifically, by its ability to enhance the expression of the transgene. An active 
transcription might influence the replication, which is an indispensable prerequisite 
for a successful segregation of plasmid DNA onto the two daughter cells in mitosis, 
i.e. plasmid retention. A clear connection between transcription and replication was 
found scanning a Drosophila chromosome, where transcriptional activity was shown 
to correlate with the replication timing, i.e. a densely transcribed domain replicated 
earlier in S-phase [124]. This phenomenon has also been reported in other work 
[125, 126]. One explanation to this interrelation of the two processes could be found 
in their similarities. Both transcription and replication are highly organized -temporally 
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and spatially- and demand the assembly of high order protein complexes as well as 
chromatin decondensation. They are locally restricted in transcription factories [127, 
128] and replication foci [129-133], areas where the needed enzymes and factors are 
concentrated to facilitate the initiation and onset of these processes. Depending on 
transcriptional activity gene domains are localized in different subnuclear positions, 
pending between the nuclear periphery and heterochromatin for transcriptionally 
inactive genes to the euchromatin for active gene loci [134, 135]. One hypothesis 
why an active transcription leads to an early replication in S-phase is that the earliest 
replication complexes form at the location where they can assemble easiest, which 
would be proximal to active genes in the open euchromatin [136]. This would lead to 
the assumption that transcription and replication factories are also spatially 
connected to each other, preventing the need of transport of the genes from 
transcriptional sites to replication foci. Indeed, there has been evidence for a global 
colocalization in the nucleus at the onset of S-phase [137], but there is hardly any 
evidence for a direct over-lapping of the two functional foci [138]. Judging from the 
distribution pattern of the factories there is likely a discontinuous dynamical zonal 
change from transcription factory areas into replication factories areas, where 
transcription factories in a distinct zone are decommissioned and replication factories 
are established instead. When replication is finished, replication factories are 
disintegrated and transcription starts again. Thereafter, the next zone is turned into a 
replication factories area for the restricted time of replication [139, 140]. In any case, 
there seems to exist a temporal replication advantage for actively transcribed genes 
since these will automatically be in the area of early replication. In addition, it can be 
speculated that the binding of the transcription factors and transcriptional machinery 
units to their cognate sites could facilitate replication by preparing DNA for the 
unwinding process, since both events demand the separation and unwinding of the 
two DNA strands. We therefore hypothesise that by increasing the transcription and 
subsequent expression of the transgene indirectly also the replication and retention 
of the plasmid DNA, two important factors for achieving a prolonged and strong gene 
expression for gene therapy, will improve. 
Seeing the clear advantage of the human CMV-enhancer over the murine we 
decided to examine if a second copy of the human CMV-enhancer could enhance the 
transgene expression even more, as in previous cases; [141-143]. As seen in fig 5, 
the second enhancer does not lead to better expression. On the contrary, it 
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decreases the expression level in the beginning, is however delaying the drop in 
signal and reaches the same level as the plasmid with one enhancer after the signal 
drop. Since the assembly of the enhanceosome and the interaction with the core 
promoter and associated factors seem to be a complex process [144-149] it is likely 
that a second enhancer is not coercively increasing the transcription rate. In this 
case, in the two first weeks of the experiment, it seems like the second enhancer is 
rather delaying the transcription initiation than promoting it. Most probably it is 
depending on the nature of the enhancer if a second sequence is additive -or even 
synergistic- or if it is merely hindering the process. It has been shown that the hCMV 
enhancer is modularly built, with several different repeated sequences. A single copy 
of the 18bp or 19bp repetitive sequence alone was able to drive expression from the 
minimal core promoter, with the 19 bp repeat, containing the binding site for ATF, 
being the strongest one. By repeating these sequences the expression was 
increased, even though the activation by the natural full length enhancer always was 
superior [150]. This shows the modular nature of the enhancer, where the single 
modules (enhansons) can act separately to initiate transcription. By interaction with 
other modules and their associating activators the enhancing effect on the 
transcription can be incremented accordingly. The enhancer sequence in pCpG-
hCMV/EF1-LucSH is not the full length of the naturally occurring enhancer, but is 
containing 15 consensus sequences of binding sites for ATF and numerous other cis-
acting factors. It has presumably conserved some of its integrative modular function, 
and even though the multiplication of the 19bp repeat was leading to increased 
expression, this must not be the case of the longer and, probably, much more 
complex enhancer of pCpG-hCMV/EF1-LucSH. 
4.2. Adaptive immune system is involved in transgene regulation in 
vivo 
A loss of transgene signal can have many causes, but generally depends on either: i) 
silencing of the transgene, i.e. by DNA methylation,  ii) loss of plasmid during, for 
example, mitosis or iii) elimination of transfected cells by apoptosis or immune cells. 
So what could be the cause of the rapid decrease of transgene signal of pCpG-
mCMV/EF1-LucSH and pCpG-hCMV/EF1-LucSH after hydrodynamic delivery (fig. 
3)? One option would be that it is the result of a transgene silencing effect induced by 
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methylation. This is not very likely since the plasmids pCpG-mCMV/EF1-LucSH and 
pCpG-hCMV/EF1-LucSH are CpG-reduced. They contain 16 CpG´s in the hCMV 
enhancer and none in the mCMV enhancer, and only 3 CpG´s in the rest of the 
plasmid. The three CpG´s in the backbone of pCpG-mCMV/EF1-LucSH are most 
likely not enough for triggering a formation of heterochromatin [98] and, in addition, a 
strong promoter, such as the EF-1, could be able to override a weak repression [96]. 
In pCpG-hCMV/EF1-LucSH, in theory, 16 methylated CpG´s in the enhancer could 
trigger transcriptional repression, as shown by Kass et al [96], where a similar 
number (9-21) of methylated CpG´s could decrease the transgene expression, 
independent of their location in the plasmid. But this decrease was maximum 2-fold 
and stands in no comparison to the decrease in expression observed with pCpG-
mCMV/EF1-LucSH and pCpG-hCMV/EF1-LucSH (10 000-fold decrease). For a 
repression over the human CMV enhancer it would probably also necessitate a 
complete methylation of all its CpG´s, since the length of the methylated CpG-island 
is decisive for the repression [96, 97]. In comparison to the CpG-reduced plasmids, 
pEGFPLuc contains several hundreds of CpG´s evenly spread over the whole 
sequence and its CMV-IEP is known from previous work to be methylated fast [26, 
27]. This is probably also occurring, since the signal from pEGFPLuc is plummeting 
from the first day on (fig. 6). In contrary to this, the signal from pCpG-mCMV/EF1-
LucSH and pCpG-hCMV/EF1-LucSH is decreased only 2 weeks after injection. This 
points to that the signal from pCpG-mCMV/EF1-LucSH and pCpG-hCMV/EF1-LucSH 
is decreased by the same mean and probably not by methylation.  
The decrease in transgene signal does also not seem to be the result of a loss of 
plasmid during cell cycling, since this would have been expected to occur mainly 
directly after the hydrodynamic injection, when the regeneration of the liver after the 
hydrodynamic delivery largely occurs. Instead, the signal is relatively stable the first 2 
weeks after treatment.  
The last alternative, elimination of the transfected cells, could be the result of direct 
apoptosis of cells severely damaged from the hydrodynamic treatment or by 
apoptosis or destruction of the transfected cells influenced by the immune system. 
The apoptosis induced by cell damage is not likely, since this would also have 
happened primarily directly after injection, so the most probable cause for the signal 
drop is by influence of the immune system. 
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To test if the immune defence is actually the leading factor, the plasmids pCpG-
mCMV/EF1-LucSH, pCpG-hCMV/EF1-LucSH, pCpG-2xhCMV/EF1-LucSH and 
pEGFPLuc were injected into SCID mice, lacking mature T- and B-cells and therefore 
a functional adaptive immune system. The resulting expression profile of pCpG-
mCMV/EF1-LucSH, pCpG-hCMV/EF1-LucSH and pCpG-2xhCMV/EF1-LucSH in the 
immunodeficient mice (fig. 7) is clearly deviating from the profile in the 
immunocompetent Balb/C mice (fig. 3 and 5). In the immunodeficient mice the 
transgene signal is stable over time, without any loss of strength, whereas it is 
reduced in the immunocompetent mice. Only in the case of pEGFPLuc the 
expression-over-time pattern is the same in both immunocompetent and 
immunodeficient mice (fig. 6 and 7). This clearly shows that the signal from 
pEGFPLuc is silenced without the influence of the T- and B-cells, probably by DNA 
methylation, and that the adaptive immune defence is playing a crucial role in the 
regulation of the transgene signal of pCpG-mCMV/EF1-LucSH, pCpG-hCMV/EF1-
LucSH and pCpG-2xhCMV/EF1-LucSH.  
Most probably, the gene product of the luciferase::Sh gene is immunogenic, acting as 
an antigen to trigger the cellular and/or humoral host response. This would 
correspond to the finding of the group of Davis et al where muscle fibres were 
destroyed around 10 days after injection of an antigen-expressing plasmid, and when 
co-injecting with a luciferase-expressing plasmid, they could see strong luciferase 
expression still at day 5 and a >99% loss by day 20 [151]. They noted an activation of 
CD8+ cytotoxic T lymphocytes 3-6 days after injection, which reached a maximum at 
6-12 days [152]. This temporal pattern of immune cell activation and elimination of 
transfected cells and consequent decrease of transgene expression fits to the 
delayed drop of luciferase signal of pCpG-mCMV/EF1-LucSH, pCpG-hCMV/EF1-
LucSH and pCpG-2xhCMV/EF1-LucSH. It must be noted, though, that the gene 
product of the luciferase-expression plasmid Davis et al used was on its own not 
causing a decrease in signal, i.e. immune reaction. On the other hand, the luciferase 
used in Davis work and the LucSH used here are not the same, since the luciferase 
gene in LucSH is fused to another gene and is additionally modified to remove CpG-
dinucleotides.  
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4.3. Plasmid retention is dependent on cell growth activity   
The human enhancer was clearly advantageous compared to the murine enhancer in 
driving the expression in the liver and we wanted to investigate this effect also in a 
tumour model. For this purpose, SCID mice carrying subcutaneous human tumours 
were electroporated with the plasmids pCpG-mCMV/EF1-LucSH, pCpG-hCMV/EF1-
LucSH, pCpG-2xhCMV/EF1-LucSH and pEGFPLuc and the consequent luciferase 
expression was followed by in vivo imaging. The cell line we used for the 
subcutaneous model was MDA MB-435, which lately attracted some attention 
because of its rather uncertain identity. It was used for a long time as a standard cell 
line for research on breast cancer. After examination of its expression profile doubts 
about its origin came up, since it resembled more the melanocytic lineage than the 
mammary cancer cell lines [153, 154]. But later investigations revealed that it did 
show most of the characteristics of the epithelial breast cancer lineage, but has 
probably with time delineated and is now expressing also melanocyte-specific 
proteins [155]. Indifferent of its exact cell type, we decided to use this cell line since it 
forms slow growing subcutaneous tumours, giving us time to follow the plasmid faith 
in a tumour environment.  
The result shows a relatively stable luciferase signal in the tumours over time, with 
none of the plasmids exhibiting a significantly better retention potential than the 
others (fig. 8A). In the case of the plasmids pCpG-hCMV/EF1-LucSH, pCpG-
mCMV/EF1-LucSH and pCpG-2xhCMV/EF1-LucSH this coincides with the 
expression pattern in the liver of the immunodeficient mice (fig. 7), where the 
luciferase signal, due to the lack of an adaptive immune system, is also not changing 
over a long period of time.  What was surprisingly different when comparing the 
transgene expression in the liver and tumour is the expression from the plasmid 
pEGFPLuc. In the tumour its transgene signal is stable, whereas the signal is 
abruptly decreased in the liver. The reason for this might be found in its promoter, 
CMV-IEP, and its interaction with the tumour cells. 
The MDA MB-435 cells have been shown to have a constitutively active NFκB, which 
is probably partly the result of decreased levels of the IκB-α and -β [156] and a lack 
of oestrogen receptor (ER), which can reduce the NFκB in various ways [156]. It is 
said that this active transcription factor allow ER-negative breast cancer cells to grow 
in a non-oestrogen dependent manner and also survive radiation and chemotherapy 
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treatment since it prevents apoptosis. Other target genes of NFκB influence 
angiogenesis, inflammation, degradation of extracellular matrix and cell adhesion, 
which could be why ER-negative breast cancer is often associated with invasiveness 
and metastasis, accompanied with a poor prognosis.  NFκB is activated by various 
stimuli, such as cellular or environmental stress, cytokines, DNA-damage, radiation 
or pathogens [157]. To the last category also CMV infection counts, where 
glycoproteins of the virus envelop or immediate-early gene products trigger the 
nuclear translocation of the transcription factor [158-160]. This NFκB activation, 
which leads to an inflammatory response aiming at fighting the virus, has been taken 
advantage by the CMV by incorporating several functional NFκB binding sites into its 
immediate-early gene promoter/enhancer. Thus, the binding of NFκB to these sites 
leads to a priming of expression of the immediate-early genes [22, 161]. NFκB is also 
able to reactivate latent CMV. This was shown by treating transgenic mice 
expressing the β-galactosidase under the control of the CMV-promoter with 
adenovirus. The adenovirus induced the formation of active NFκB and the 
reactivation of the β-galactosidase expression, both coinciding temporally with each 
other [162]. Taking together that MDA MB-435 cells harbour a constitutively active 
NFκB and that this transcription factor is able to increase the level of gene 
expression by binding to the hCMV-IEP, it is possible that this is the reason to why 
the CMV promoter is not silenced in the MDA MB-435 tumours.  
In contrary to the stable signals from all the plasmids in the tumour, the transgene 
signal was not measurable anymore after about 2 weeks when the in vivo 
electroporated and passaged MDA MB-435 tumour cells were taken into cell culture 
(fig. 9) or when the cells where transfected directly in vitro (fig. 10). This is probably 
due to the faster cell growth in vitro compared to the tumour. A phenomenon 
underlining this was observed when transfecting cycling or quiescent primary smooth 
muscle cells. While the transgene signal from the quiescent cells was stable for more 
than one month, the signal from the freely growing cells was lost after 3 weeks (fig. 
11). Apparently, cell growth can lead to a loss of plasmid material. This can happen 
during mitosis when the nuclear membrane is disrupted, enabling the plasmid DNA to 
distribute into the cellular compartment. When the nuclear membrane is re-
established in telophase, the plasmids which are not in close proximity to the 
chromosomes will be excluded from the newly formed nucleus. Alternatively, or 
additionally to this, over-growth of transfected cells by untransfected cells (which 
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could have a metabolic advantage not having to express a large transgene), can lead 
to a loss of transgene signal in cycling cells. 
For future gene therapy approaches these results are important to bear in mind when 
trying to reach a persistent transgene expression. If the target cells are slow dividing 
or quiescent the problems with loss of plasmid DNA are minor, such as in the case of 
muscle fibre cells, where plasmids can be retained in an extrachromosomal actively 
transcribing state over several months [163]. If the target cells, on the other hand, are 
constantly cycling, like for example skin cells, one will need a plasmid vector which is 
stably retained also during mitosis. 
 
4.4. Efficient immune response requires minimal amount of 
transgene 
Nature has developed many strong and ubiquitous expression systems with time and 
the succession to even stronger or better controllable systems are now investigated 
by gene technology and synthetic production in an accelerating pace. By combining 
already existing enhancers and promoters hybrid control elements are created, some 
more efficient in gene expression than the cognate enhancer-promoter, for example 
the promoter CAG, which is composed of the CMV enhancer and chicken β-actin 
promoter [164]. Aside shuffling of known enhancers and promoters, the construction 
of new synthetic regulatory elements open up totally new combinatorial possibilities. 
By combining the homologous regions of 2 strong ubiquitous promoters, the EF-1 
and CMV-IEP, our aim was to bring together the advantages of both promoters. The 
CMV-IEP is one of the strongest promoters commercially used, but suffers from 
silencing events, whereas the EF-1, being of human origin, lacks the pronounced 
silencing effect, but gives short-term weaker transgene expression than the CMV-
IEP. The promoters show innate high homology (44%) and by combining and 
optimizing these homologous regions the synthetic promoter SCEP was formed. 
SCEP shows a high similarity with the 2 parental promoters (74% and 60% to EF-1 
and CMV respectively) but exhibits some interesting new features. It renders higher 
transgene expression values than both CMV and EF-1 promoter and additionally 
escapes the initial silencing, the characteristic of CMV-IEP.  
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Interestingly, the signal from pCpG-hMCV/SCEP-efFLuc undergoes the same 
decrease in strength 2 weeks after injection as pCpG-hMCV/EF-1-efFLuc. This 
implies that pCpG-hMCV/SCEP-efFLuc also is subjected to an immune response by 
the host cell defence. The signal from pCpG-hCMV/CMV-eFLuc, on the other hand, 
does not exhibit this signal drop, even though it expresses the same transgene 
product, which could be recognized by an APC as an antigen, thus triggering a 
specific immune response against transfected cells. We hypothesise that the amount 
of produced luciferase is the key point and that a certain threshold  level of luciferase 
must be produced to trigger an immunologic reaction strong enough to affect 
transgene expression. A similar observation was made when Labarriere et al [165] 
examined the mRNA levels of tumour antigens in melanoma cell lines and their ability 
to elicit an antigen specific cytotoxic T lymphocyte (CTL) response. The result 
showed that a critical lower level of antigen mRNA was necessary to trigger IL-2 
expression (a strong autocrine activator for TH-cells) and that CTL lytic activity was 
grossly proportional to antigen transcription. This indicates that the amount of MHC I 
bound antigen presented on the tumour cell surface is decisive for the activation of T 
cells; a conclusion also found by Rawson et al [166]. They hypothesise that multiple 
protein epitopes are necessary to elicit an effective antigen specific immune reaction, 
something which is promoted by higher transgene expression and subsequent 
digestion and presenting on the cell surface. 
4.5. Minicircles lead to enhanced transgene expression in vivo 
A highly efficient process for minicircle production has been developed using the 
ParA resolvase recombinase, with a recombination efficiency of >99,5 %, combined 
with an affinity chromatography approach for purification, leading to a purity of 
>98,5% [117]. For the biological testing of a minicircle manufactured according to this 
procedure, pCMV-Luc-MC, it was compared with its parental plasmid, pCMV-Luc, in 
vitro and in vivo. In general, the pCMV-Luc-MC was performing equally well 
independent if it was applied in equimolar or equal weight ratios to pCMV-Luc. In 
vitro the transfection with the minicircle led to a higher transgene expression in 
PSMC cells (fig. 14). The better performance is probably due to facilitated uptake 
and trafficking of the smaller minicircle, but this feature seems to be cell type specific, 
since the expression from the minicircle and parental plasmid was similar in N2A 
cells. 
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By injection of the two plasmids in equimolar amounts by hydrodynamic delivery in 
mice the transgene expression was monitored in the liver over time (fig. 15, 16). The 
resulting data show a difference in luciferase activity between the plasmids only in 
the highest applied concentration of pDNA, with the signals from the minicircle being 
superior. In the lower pDNA concentrations no difference between minicircle and 
plasmid was seen.  
By reducing the number of unmethylated CpG´s in the plasmid sequence the 
negative effect of DNA methylation and inactivation of plasmid, promoter attenuation 
and immune reactions can theoretically be reduced. The CMV promoter is known to 
be inactivated fast by promoter methylation [26, 27], and here it probably also is, 
judging from the fast decrease in transgene signal from both plasmids directly after 
injection. Additionally to this, it has been shown that also methylation of other 
sequences in the plasmid leads to decreased gene expression [93, 96-98].  This 
could cause higher repression of the parental plasmid in comparison to the minicircle. 
But the effect of silencing by DNA methylation is not plasmid dose-dependent; hence, 
if DNA methylation would be the driving force to the reduced transgene signal, there 
should be a difference in transgene expression between minicircle and plasmid in all 
pDNA concentrations. But there is only a difference in the highest plasmid 
concentration, therefore this mechanism can largely be ruled out.  
The other possible explanations to the different expression level between parental 
plasmid and minicircle are promoter attenuation and immune reactions. These 
alternatives are more likely, since they are both plasmid dose-dependent: The more 
unmethylated CpG´s there are in the cells, the more pro-inflammatory cytokines are 
produced [69], which can bind to and reduce the expression from the promoter [76-
80] or activate the immune system to trigger a transgene specific immune reaction 
more efficiently [73,74].  
Minicircle production as an alternative to reduce CpG´s, and also to reduce plasmid 
size, is one option to take into consideration when producing a vector for gene 
therapeutic purposes. Especially with the improved production process, promising 
high efficiency and facilitated purification, the production can be scaled-up for 
commercial sales.  
4 Discussion  59 
 
4.6. Transcriptional targeting with AFP promoter/CMV enhancer 
By using transcriptional targeting the aim was to increase safety of liver gene therapy 
by reducing side effects associated with gene expression in extrahepatic cells. The 
main problem with the tested liver specific promoters was a relative low expression 
level in vitro and in vivo relative to the CMV promoter (fig. 18 and 20). This could be 
problematic when trying to reach therapeutic levels of a transgene. By introducing the 
enhancer sequence from the hCMV an increase in transgene expression was 
observed for all liver-specific promoters tested, most prominent in the case of the 
AFP promoter (fig. 21). Since the CMV-IEP is not liver-specific but renders 
ubiquitous gene expression, the risk by combining the hCMV enhancer with the AFP 
promoter could have been a loss of the tissue-specificity. As seen in fig. 22 only low 
expression in non-HCC cell lines was observed, hence the chimeric enhancer-
promoter is still activated mainly in HCC. The special characteristic of the natural 
AFP promoter compared to the other investigated liver specific promoters is its 
specificity for HCC cells, since it is silenced in adult liver tissue [42]. Therefore, the 
AFP promoter is suitable for targeted HCC gene therapy. 
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5. Summary 
Gene therapy poses a relatively new approach for treatment of various diseases (first 
gene therapy clinical trial in 1990). It is still on an experimental basis and there will be 
still research needed before the first gene therapy product will be accepted for 
commercial sale. The major hurdles for reaching this so far have been safety and 
efficiency, two problems generally associated with viral and nonviral gene therapy, 
respectively. To avoid the safety issues arising from viral delivery, such as reported 
insertional mutagenesis and severe immune responses, lately the focus has been 
turned to nonviral vectors. To deal with the low efficiency of these vectors much work 
has been done on the gene transfer vehicle of the DNA cargo, i.e. liposome and 
polyplex formulations, for example. But also the construction of the DNA itself, the 
plasmid, can influence the gene therapy potential considerably, as reported in this 
thesis.  
By choosing and combining the modules of the plasmids in an optimised way, 
transgene expression can both be enhanced and prolonged. This has been shown by 
combining a ubiquitous EF-1 promoter with a CMV enhancer, the latter originating 
either from murine or human CMV. The plasmid with the human CMV enhancer 
showed clearly a higher and longer-lasting transgene expression in vivo in 
comparison with the murine analogue, probably due to a better promoter-enhancer 
interaction. This advantage in expression was also paired with a higher plasmid copy 
number, showing that a high expression of a plasmid leads to a better retention 
thereof in the host cell, an important factor for gene therapy. In all cases with 
plasmids containing mCMV or hCMV enhancers, the transgene signal is first 
constant, but drops abruptly about 2 weeks after application. To clarify the reason for 
this sudden reduction of signal the experiment was repeated in immunodeficient 
mice. The result showed, in contrast to previous measurements, stable expression 
signals, indicating that the immune system was responsible for the loss of transgene 
signal. We could also show that a high level of transgene expression was necessary 
to trigger such an immune response: A plasmid with a CMV promoter showed similar 
expression profiles in both immunocompetent and –deficient mice; a sharp decrease 
from day one after application, which within a few days after application stabilised on 
much lower levels, but showed no further decrease 2 weeks after application. The 
early signal drop is probably due to previously reported methylation of the CMV 
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promoter and leads to lower transgene signals, which do not elicit a strong immune 
response. 
The strong, viral CMV promoter suffers from early silencing processes, whereas the 
signal from the mammalian EF-1 promoter is more stable. With the idea of taking 
advantage of the best features of the two, a new synthetic promoter was designed by 
combining the shared homologous regions. The novel promoter, SCEP, showed 
enhanced transgene signals in vivo compared to both the CMV and EF-1 promoter, 
but elicited, because of the high levels of transgene product, in the same fashion as 
the EF-1 containing promoter, an immune response, which led to a drop in signal two 
weeks after plasmid injection. The two luciferase variants used here as reporter 
genes are apparently mitogenic, thus, reduces the longevity of their expression. 
Therefore, it would be of great interest to investigate other transgenes, i.e. 
endogenous therapeutic genes with less or no immunological effect, to evaluate if the 
stability of the gene expression can be increased and to which extent. 
The transgene signal durability is also connected with the cycling frequency of the 
transfected cells, as shown in a slow-growing tumour model. The plasmids were 
introduced into the tumours by electroporation and the tumour cells were isolated and 
taken into cell culture directly or two weeks after electroporation. Measurements of 
the transgene signal revealed constant levels in the tumours over one month time, 
whereas the signal in the cell culture, where the cell doubling time is considerably 
shorter, was lost within 2 weeks. This result points to the event of mitosis as a 
decisive time point when plasmids easily are lost, and should be taken into 
consideration when choosing the target cells for gene therapy. 
One way of reducing plasmid loss caused by the host immune defence is to minimise 
the amount of unmethylated CpG´s in the plasmid sequence. Reduction of the CpG´s 
can be done either by an overall elimination at the step of plasmid design, or later in 
the plasmid production process by removing the bacterial backbone, containing most 
of the unmethylated CpG´s. Thus, a minicircle is formed, containing only the 
mammalian expression cassette. By a highly efficient, novel production process one 
model minicircle was produced and in this work tested biologically. The minicircle 
showed an advantage against the corresponding full-length plasmid in higher 
application concentrations in vivo. The approach of minicircles is therefore a 
promising part of the puzzle to complete an efficient therapeutic vector, especially 
since its production now is efficient enough to be scaled up. 
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One last area of plasmid regulation design evaluated in this work concerned the 
transcriptional control using liver specific promoters. Compared to the CMV promoter 
these liver specific promoters were generally weaker, but the transcriptional strength 
could be enhanced by combination with a hCMV enhancer. The strongest of the 
tested hybrid liver promoter/ hCMV enhancer was based on the AFP promoter, which 
is silent in adult liver tissue and reactivated in most HCC. It was tested in vitro and 
the result showed a low transgene expression in off-target cell lines and high in HCC 
cell lines, a feature which can be used for transcriptional targeting of cancer cells in 
the treatment of HCC. 
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6. Appendix 
6.1. Abbreviations 
AFP α-fetoprotein 
AMP adenosine monophosphate 
Amp ampicillin resistance gene 
AP-1, AP-2 activating protein 1, 2 
APC antigen presenting cell 
ATF activating transcription factor 
BCG bacille Calmette Guérin 
bp base pair 
BRE TFIIB recognition element 
BSA bovine serum albumin 
c/p-ratio  Weight ratio of conjugate to plasmid  
cAMP cyclic adenine monophosphate 
cDNA complementary DNA 
CMV   Cytomegalovirus 
CMV-IEP cytomegalovirus immediate early promoter 
CpG cytosine-guanine dinucleotide 
CRE cyclic AMP response element 
CREB cAMP response element binding 
CTF CAAT (controlled amino acid treatment) transcription factor 
DC dendritic cell 
DMEM Dulbecco´s modified Eagle´s medium 
DMSO              Dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DPE down-stream promoter elements 
DTT   Dithiothreitol 
E. coli Escherichia coli  
EBV Epstein-Barr virus 
EC endothelial cell 
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EDTA ethylenediaminetetraacetic acid 
EF-1 elongation factor-1α 
eFLuc enhanced firefly luciferase 
EGFP enhanced green fluorescent protein 
ER endoplasmic reticulum 
EtBr Ethidium bromide 
FCS Fetal calf serum 
Fig. figure 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFAP glial fibrillary acidic protein 
GLuc Gaussia princeps luciferase 
HBS HEPES-buffered saline 
HBV hepatitis B virus 
HCC hepatocellular carcinoma 
hCMV, mCMV human, murine cytomegalovirus 
HDAC histone deacetylase 
HEPES N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid) 
hK2 human glandular kallikrein 2 
HSV tk herpes simplex virus thymidine kinase gene 
i.p. intraperitoneal 
i.t. intratumoral 
i.v. intravenous 
IFN interferon 
IKK IκB-kinase complex 
IL interleukin 
Inr initiator 
IRAK1, IRAK4 IL-1 receptor associated kinase 1, 4 
IκB inhibitor of NFκB (nuclear factor κB) 
Kan/Neo neomycin phosphotransferase gene 
lacI repressor of lactose operon 
lacO lactose operator 
LPEI linear polyethyleneimine of a Mw of 22 kDa 
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LPS lipopolysaccharide 
LRR leucin-rich repeat 
Luc luciferase 
MAP mitogen-activated protein 
MBD 1-3 methyl CpG binding domain protein 1-3 
MBP myelin basic protein 
MCS multiple cloning site 
MeCP2 methyl CpG binding protein 2 
MHC major histocompatibility complex 
mRNA messenger RNA  
MyD88 myeloid differentiation primary-response protein 88 
N/P-ratio Molar ratio of PEI nitrogen to DNA phosphate 
NFκB nuclear factor 'kappa-light-chain-enhancer' of activated B-cells  
NIS sodium iodide symporter 
NK natural killer cell 
ODN oligodeoxynucleotide 
ori origin of replication 
p/s photons per second 
PAMP pathogen-associated molecular pattern 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
pDNA plasmid DNA 
polyA polyadenylation signal 
PSMA prostate specific membrane antigen 
PSMC porcine smooth muscle cell 
QPCR real-time PCR  
RLU Relative light units 
RNA ribonucleic acid 
RNAPol RNA polymerase 
RSV rous sarcoma virus 
S/MAR scaffold matrix attachment region 
SAF-A scaffold attachment factor A 
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SV40 simian virus 40 
TAB1, TAB2 TAK1-binding protein 1, 2 
TAK1 transforming growth-factor-β-activated kinase 1 
TH T helper cell 
TIR Toll/IL-1 receptor 
TLR toll-like receptor 
TNF-α tumour necrosis factor α 
TRAF6 TNF receptor associated factor 6 
UBC13 ubiquitin-conjugating enzyme 13 
UEV1A ubiquitin-conjugating enzyme E2 variant 1 
UTR untranslated region 
w/w weight to weight ratio 
Zeo zeosine resistance gene 
β-Glo β-globuline 
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6.2. Publications 
6.2.1. Poster presentations 
• Terese Magnusson, Verena Russ, Isabella Stapff, Rudolf Haase, Ernst Wagner 
and Manfred Ogris: Optimising synthetic ex vivo transferrin mediated transfection 
of the erythroleukemia cell line K562 with episomal plasmids, DGGT, 2008, Berlin, 
Germany  
 
• Terese Magnusson, Rudolf Haase, Armin Baiker, Ernst Wagner and Manfred 
Ogris: Sustained, high transgene expression in liver with CpG-free plasmids using 
optimised promoter-enhancer combinations, combined ESGCT and DGGT, 2009, 
Hannover, Germany. 
 
• Rudolf Haase, Terese Magnusson, Ernst Wagner and Manfred Ogris: Generation 
of the novel, synthetic hybrid SCE promoter for gene-therapeutical applications, 
DGGT, 2010, Munich, Germany. 
 
6.2.2. Publications 
• Rudolf Haase, Orestis Argyros, Suet-Ping Wong, Richard P Harbottle, Hans J 
Lipps, Manfred Ogris, Terese Magnusson, Maria Vizoso Pinto, Jürgen Haas, 
Armin Baiker: pEPito: a significantly improved non-viral episomal expression 
vector for mammalian cells, BMC Biotechnol., 2010, 10-20. 
 
• Sina Rupprecht, Claudia Hagedorn, Davide Seruggia, Terese Magnusson, Ernst 
Wagner, Manfred Ogris, Hans J. Lipps: Controlled removal of nonviral episomal 
vector from transfected cells, Gene, 2010, 466 (1-2): 36-42 
 
• Philipp Dussmann, Judith I. Pagel, Sabina Vogel, Terese Magnusson, Rene 
Zimmermann, Ernst Wagner, Wolfgang Schaper, Manfred Ogris, Elisabeth Deindl: 
Live in vivo imaging of Egr-1 promoter activity during neonatal development, liver 
regeneration and wound healing. Submitted. 
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• Terese Magnusson, Rudolf Haase, Ernst Wagner and Manfred Ogris: Sustained, 
high transgene expression in liver with CpG-free plasmids using optimized 
promoter-enhancer combinations. Submitted. 
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